PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 22543687-10 2012 This effect of Rib-BSA is reversed by pretreatment of pioglitazone and rosiglitazone, which belongs to thiazolidinediones (TZDs) and are peroxisome proliferator-activated receptor (PPAR-gamma) ligands. Pioglitazone 54-66 peroxisome proliferator-activated receptor gamma Rattus norvegicus 181-191 22076494-1 2012 This study aimed to investigate the possible relationship between ovarian functionality and the oxidative response during cystogenesis induced by hyperandrogenization with letrozole and examine protective effect of the peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist, pioglitazone (PIO), in polycystic ovary (PCO). Pioglitazone 290-302 peroxisome proliferator-activated receptor gamma Rattus norvegicus 269-279 22076494-1 2012 This study aimed to investigate the possible relationship between ovarian functionality and the oxidative response during cystogenesis induced by hyperandrogenization with letrozole and examine protective effect of the peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist, pioglitazone (PIO), in polycystic ovary (PCO). Pioglitazone 304-307 peroxisome proliferator-activated receptor gamma Rattus norvegicus 269-279 22970990-2 2012 Pioglitazone and rosiglitazone possess a common functional core, glitazone, which is considered a privileged scaffold upon which to build a drug selective for a given target--in this case, PPARgamma. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 189-198 22819112-0 2012 Pioglitazone, a peroxisome proliferator activated receptor gamma agonist, decreases renal crystal deposition, oxidative stress and inflammation in hyperoxaluric rats. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 16-64 22819112-2 2012 The peroxisome proliferator activated receptor gamma agonist pioglitazone (AK Scientific, Union, California) is used to treat type 2 diabetes mellitus with an adjunctive effect that improves glycemic control and has anti-inflammatory and antioxidative effects. Pioglitazone 61-73 peroxisome proliferator-activated receptor gamma Rattus norvegicus 4-52 22387860-3 2012 Here we have examined the effect of pioglitazone, an agonist of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), on renal lipid accumulation and renal injury induced by angiotensin II infusion. Pioglitazone 36-48 peroxisome proliferator-activated receptor gamma Rattus norvegicus 68-116 22389055-0 2012 Pioglitazone, PPARgamma agonist, attenuates experimental autoimmune neuritis. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 14-23 22389055-1 2012 Recent advances demonstrate peroxisome proliferator-activated receptors gamma (PPARgamma) agonist, pioglitazone, as an anti-inflammatory drug. Pioglitazone 99-111 peroxisome proliferator-activated receptor gamma Rattus norvegicus 79-88 22389055-4 2012 Pioglitazone ameliorated the clinical score of EAN, decreased expression of TNF-alpha, IFN-gamma, and the activation of NF-kappaB, while increasing the expression of PPARgamma and IL-4. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 166-175 22677361-0 2012 Pioglitazone, a PPAR-gamma activator, attenuates the severity of cerulein-induced acute pancreatitis by modulating early growth response-1 transcription factor. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 16-26 22677361-6 2012 In vitro, a PPAR-gamma activator (pioglitazone) strikingly diminished Egr-1 mRNA and protein expression corresponding to Egr-1. Pioglitazone 34-46 peroxisome proliferator-activated receptor gamma Rattus norvegicus 12-22 22387860-3 2012 Here we have examined the effect of pioglitazone, an agonist of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), on renal lipid accumulation and renal injury induced by angiotensin II infusion. Pioglitazone 36-48 peroxisome proliferator-activated receptor gamma Rattus norvegicus 118-128 22136281-3 2012 The objective of this study was to investigate the effect of pioglitazone (Pio), a synthetic PPAR-gamma ligand, on the development of peritoneal fibrosis in CG-induced EPS rats. Pioglitazone 61-73 peroxisome proliferator-activated receptor gamma Rattus norvegicus 93-103 21954843-0 2012 PPAR-gamma activator pioglitazone prevents age-related atrial fibrillation susceptibility by improving antioxidant capacity and reducing apoptosis in a rat model. Pioglitazone 21-33 peroxisome proliferator-activated receptor gamma Rattus norvegicus 0-10 22179086-3 2012 This study analyzes the effect of pioglitazone, a PPARgamma agonist, on interleukin-1beta-induced COX-2 expression and the role of reactive oxygen species (ROS) on this effect. Pioglitazone 34-46 peroxisome proliferator-activated receptor gamma Rattus norvegicus 50-59 22179086-11 2012 In addition, pioglitazone increased the interleukin-1beta-induced PPARgamma mRNA levels. Pioglitazone 13-25 peroxisome proliferator-activated receptor gamma Rattus norvegicus 66-75 22179086-12 2012 CONCLUSION: PPARgamma activation with pioglitazone reduces interleukin-1beta-induced COX-2 expression by interference with the redox-sensitive transcription factor NF-kappaB. Pioglitazone 38-50 peroxisome proliferator-activated receptor gamma Rattus norvegicus 12-21 22076002-6 2012 Inversely with the reduction of the infarct size, PPARgamma, and p-STAT3 but not estrogen receptor alpha in the peri-infarct area were increased in PGZ-treated compared with vehicle-control rats. Pioglitazone 148-151 peroxisome proliferator-activated receptor gamma Rattus norvegicus 50-59 22076002-8 2012 Inhibitors of PPARgamma or STAT3 abolished the PGZ-induced neuroprotection and the increase in p-STAT3. Pioglitazone 47-50 peroxisome proliferator-activated receptor gamma Rattus norvegicus 14-23 22391246-0 2012 Differential susceptibility to the PPAR-gamma agonist pioglitazone in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine rodent models of Parkinson"s disease. Pioglitazone 54-66 peroxisome proliferator-activated receptor gamma Rattus norvegicus 35-45 22391246-2 2012 The present study sought to evaluate the effect of the PPAR-gamma agonist pioglitazone in two different animal models of PD. Pioglitazone 74-86 peroxisome proliferator-activated receptor gamma Rattus norvegicus 55-65 22083161-4 2012 Two weeks after coronary artery ligation, HF rats received an intracerebroventricular infusion of the PPAR-gamma agonist pioglitazone or vehicle for another 2 weeks. Pioglitazone 121-133 peroxisome proliferator-activated receptor gamma Rattus norvegicus 102-112 22083161-8 2012 All of these findings were ameliorated in HF rats treated with intracerebroventricular pioglitazone, which increased PPAR-gamma expression and DNA binding activity in the paraventricular nucleus of hypothalamus. Pioglitazone 87-99 peroxisome proliferator-activated receptor gamma Rattus norvegicus 117-127 22240811-3 2012 Treatment of 832/13 rat INS-1-derived cells with 25 mm glucose and the proinflammatory cytokine IL-1beta led to a similar loss of SERCA2b expression, which was prevented by treatment with the peroxisome proliferator-activated receptor (PPAR)-gamma agonist, pioglitazone. Pioglitazone 257-269 peroxisome proliferator-activated receptor gamma Rattus norvegicus 192-247 22240811-8 2012 Within 2 h of exposure, activation of cyclin-dependent kinase 5 (CDK5) was observed and correlated with increased serine-273 phosphorylation of PPAR-gamma and loss of SERCA2 protein expression, findings that were prevented by pioglitazone and roscovitine, a pharmacological inhibitor of CDK5. Pioglitazone 226-238 peroxisome proliferator-activated receptor gamma Rattus norvegicus 144-154 22240811-9 2012 We conclude that pioglitazone modulates SERCA2b expression through direct transcriptional regulation of the gene and indirectly through prevention of CDK5-induced phosphorylation of PPAR-gamma. Pioglitazone 17-29 peroxisome proliferator-activated receptor gamma Rattus norvegicus 182-192 22076002-1 2012 BACKGROUND AND PURPOSE: The role of the phosphorylated signal transducer and activator of transcription-3 (p-STAT3) after cerebral ischemia by the peroxisome proliferator-activated receptor gamma (PPARgamma) agonist pioglitazone (PGZ) remains controversial. Pioglitazone 216-228 peroxisome proliferator-activated receptor gamma Rattus norvegicus 147-195 22076002-1 2012 BACKGROUND AND PURPOSE: The role of the phosphorylated signal transducer and activator of transcription-3 (p-STAT3) after cerebral ischemia by the peroxisome proliferator-activated receptor gamma (PPARgamma) agonist pioglitazone (PGZ) remains controversial. Pioglitazone 216-228 peroxisome proliferator-activated receptor gamma Rattus norvegicus 197-206 22076002-1 2012 BACKGROUND AND PURPOSE: The role of the phosphorylated signal transducer and activator of transcription-3 (p-STAT3) after cerebral ischemia by the peroxisome proliferator-activated receptor gamma (PPARgamma) agonist pioglitazone (PGZ) remains controversial. Pioglitazone 230-233 peroxisome proliferator-activated receptor gamma Rattus norvegicus 147-195 22076002-1 2012 BACKGROUND AND PURPOSE: The role of the phosphorylated signal transducer and activator of transcription-3 (p-STAT3) after cerebral ischemia by the peroxisome proliferator-activated receptor gamma (PPARgamma) agonist pioglitazone (PGZ) remains controversial. Pioglitazone 230-233 peroxisome proliferator-activated receptor gamma Rattus norvegicus 197-206 23167631-2 2012 Carcinogenicity studies suggest that the PPARgamma agonist pioglitazone and dual PPARalpha/gamma agonists such as ragaglitazar, muraglitazar, and naveglitazar may increase the risk of bladder cancer in a dose-responsive pattern in rats. Pioglitazone 59-71 peroxisome proliferator-activated receptor gamma Rattus norvegicus 41-50 22136281-3 2012 The objective of this study was to investigate the effect of pioglitazone (Pio), a synthetic PPAR-gamma ligand, on the development of peritoneal fibrosis in CG-induced EPS rats. Pioglitazone 75-78 peroxisome proliferator-activated receptor gamma Rattus norvegicus 93-103 21649861-1 2011 Recently, some PPARgamma agonists like pioglitazone, rosiglitazone, and other newer thiazolidine-2, 4-dione (TZD) derivatives have been shown to be neuroprotective in experimental model of cerebral ischemia/reperfusion (I/R) injury. Pioglitazone 39-51 peroxisome proliferator-activated receptor gamma Rattus norvegicus 15-24 21366664-5 2011 RESULTS: Pioglitazone reduced the total and striatal infarct size, neuronal degeneration in both parts of the ipsilateral SN, the loss of TH-IR neurones in the SNc and increased the number of PPARgamma-positive TH-IR neurones. Pioglitazone 9-21 peroxisome proliferator-activated receptor gamma Rattus norvegicus 192-201 21366664-6 2011 Pioglitazone protected primary cortical neurones against oxidative and excitotoxic damage, prevented the loss of neurites and supported the formation of synaptic networks in neurones exposed to glutamate or 6-hydroxydopamine by a PPARgamma-dependent mechanism. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 230-239 21893084-10 2011 It is concluded that PPAR-gamma modulators pioglitazone and rosiglitazone may be considered as potential pharmacological agents for the management of diabetes induced VaD. Pioglitazone 43-55 peroxisome proliferator-activated receptor gamma Rattus norvegicus 21-31 22332542-7 2011 CONCLUSION: The mitochondrial membrane potential of neonate rat"s myocardial cells was descend after hypoxia/ reoxygenation, while pioglitazone can interrupt the process, indicating that the activation may be relevant to peroxisome proliferator-activated receptor gamma (PPARgamma) ligand and PKC pathway. Pioglitazone 131-143 peroxisome proliferator-activated receptor gamma Rattus norvegicus 221-269 22126757-5 2011 Pretreatment with pioglitazone significantly lowered the apoptosis rate of the cardiomyocytes with hypoxia/reoxygenation injury to (8.32-+0.89)%, and this effect was antagonized by GW9662, a specific blocker of peroxisome proliferators activated receptors gamma (PPARgamma). Pioglitazone 18-30 peroxisome proliferator-activated receptor gamma Rattus norvegicus 263-272 22126757-7 2011 CONCLUSION: Pioglitazone can ameliorate neonatal rat cardiomyocyte injury induced by hypoxia/reoxygenation partially by activating PPARgamma and does not increase the expression of PKC in the cells. Pioglitazone 12-24 peroxisome proliferator-activated receptor gamma Rattus norvegicus 131-140 21276964-0 2011 Activation of nuclear PPARgamma receptors by the antidiabetic agent pioglitazone suppresses alcohol drinking and relapse to alcohol seeking. Pioglitazone 68-80 peroxisome proliferator-activated receptor gamma Rattus norvegicus 22-31 21615901-0 2011 The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats. Pioglitazone 130-142 peroxisome proliferator-activated receptor gamma Rattus norvegicus 111-121 21621740-2 2011 Pioglitazone, a peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, has recently been shown to reduce circulating plasminogen activator inhibitor-1 (PAI-1) levels in diabetes mellitus. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 16-64 21621740-2 2011 Pioglitazone, a peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, has recently been shown to reduce circulating plasminogen activator inhibitor-1 (PAI-1) levels in diabetes mellitus. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 66-75 21621740-10 2011 Taken together, it was concluded that pioglitazone could inhibit AGE-induced PAI-1 expression, which was mediated by the ERK1/2 and PPARgamma pathways. Pioglitazone 38-50 peroxisome proliferator-activated receptor gamma Rattus norvegicus 132-141 21352843-2 2011 The present study evaluated the effect of peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist pioglitazone on 11HSD1 vascular smooth muscle cells (VSMC) and compared the effect with that of corticosterone. Pioglitazone 111-123 peroxisome proliferator-activated receptor gamma Rattus norvegicus 42-90 21352843-2 2011 The present study evaluated the effect of peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist pioglitazone on 11HSD1 vascular smooth muscle cells (VSMC) and compared the effect with that of corticosterone. Pioglitazone 111-123 peroxisome proliferator-activated receptor gamma Rattus norvegicus 92-101 21558877-6 2011 Also, supplementation with the PPARgamma agonist pioglitazone or with l-arginine or hemin, substrates for NOS and HO, respectively, eliminated the unfavorable effect of CSA on isoprenaline vasodilations. Pioglitazone 49-61 peroxisome proliferator-activated receptor gamma Rattus norvegicus 31-40 21558877-8 2011 In conclusion, the activation of the HO/CO/PPARgamma cascade is probably the cellular mechanism that underlies the beneficial effect of pioglitazone on the CSA-isoprenaline interaction. Pioglitazone 136-148 peroxisome proliferator-activated receptor gamma Rattus norvegicus 43-52 21276964-6 2011 RESULTS: We showed that activation of PPARgamma receptors by pioglitazone (0, 10, and 30 mg/kg) and rosiglitazone (0, 10 and 30 mg/kg) given orally selectively reduced alcohol drinking. Pioglitazone 61-73 peroxisome proliferator-activated receptor gamma Rattus norvegicus 38-47 20824499-6 2011 RESULTS: Treatment with pioglitazone decreased the level of amylase activity, proinflammatory factors IL-6 and TNF-alpha, ameliorated pancreatic histological score, and upregulated the expression of PPARgamma mRNA. Pioglitazone 24-36 peroxisome proliferator-activated receptor gamma Rattus norvegicus 199-208 20824499-8 2011 CONCLUSIONS: Pioglitazone can be used as a therapeutic drug and relieve the damages caused by SAP, which suggests PPARgamma ligand-pioglitazone offers a potent approach for the treatment of severe acute pancreatitis. Pioglitazone 13-25 peroxisome proliferator-activated receptor gamma Rattus norvegicus 114-123 20824499-8 2011 CONCLUSIONS: Pioglitazone can be used as a therapeutic drug and relieve the damages caused by SAP, which suggests PPARgamma ligand-pioglitazone offers a potent approach for the treatment of severe acute pancreatitis. Pioglitazone 131-143 peroxisome proliferator-activated receptor gamma Rattus norvegicus 114-123 21185913-0 2011 Neuroprotective effects of pioglitazone in a rat model of permanent focal cerebral ischemia are associated with peroxisome proliferator-activated receptor gamma-mediated suppression of nuclear factor-kappaB signaling pathway. Pioglitazone 27-39 peroxisome proliferator-activated receptor gamma Rattus norvegicus 112-160 21255596-1 2011 Pioglitazone hydrochloride (PIO), a peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, was administered orally for 85 weeks at 16 mg/kg/day to male rats fed either a diet containing 1.5% ammonium chloride (acid-forming diet) or a control diet to investigate the effects of urinary acidification induced by the acid-forming diet on the tumorigenic potential of PIO in the urinary bladder. Pioglitazone 0-26 peroxisome proliferator-activated receptor gamma Rattus norvegicus 36-84 21255596-1 2011 Pioglitazone hydrochloride (PIO), a peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, was administered orally for 85 weeks at 16 mg/kg/day to male rats fed either a diet containing 1.5% ammonium chloride (acid-forming diet) or a control diet to investigate the effects of urinary acidification induced by the acid-forming diet on the tumorigenic potential of PIO in the urinary bladder. Pioglitazone 0-26 peroxisome proliferator-activated receptor gamma Rattus norvegicus 86-95 21185913-1 2011 Previous studies have demonstrated that pioglitazone (Piog), a peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, inhibits ischemia-induced brain injury. Pioglitazone 40-52 peroxisome proliferator-activated receptor gamma Rattus norvegicus 63-111 21185913-1 2011 Previous studies have demonstrated that pioglitazone (Piog), a peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, inhibits ischemia-induced brain injury. Pioglitazone 40-52 peroxisome proliferator-activated receptor gamma Rattus norvegicus 113-122 21185913-3 2011 Because NF-kappaB is known to play a major role in the pathophysiology of brain ischemia, the present study was undertaken to elucidate whether pioglitazone attenuates ischemic neuronal damage through PPARgamma-mediated suppression of NF-kappaB apoptotic signaling pathway. Pioglitazone 144-156 peroxisome proliferator-activated receptor gamma Rattus norvegicus 201-210 21532147-2 2011 In the present study, we investigated the effects of pioglitazone, a peroxisome proliferator activated receptor gamma (PPARgamma) agonist, on AGE-induced rat VSMC growth and the underlying mechanism. Pioglitazone 53-65 peroxisome proliferator-activated receptor gamma Rattus norvegicus 69-117 21563652-6 2011 Pioglitazone (PGZ) is an agonist of peroxisome proliferator-activated receptor gamma (PPARg), itself a member of the nuclear receptor superfamily, responsible for the modulation of a number of metabolic pathways, including cell differentiation, metabolism of lipids and inflammation. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 36-84 21563652-6 2011 Pioglitazone (PGZ) is an agonist of peroxisome proliferator-activated receptor gamma (PPARg), itself a member of the nuclear receptor superfamily, responsible for the modulation of a number of metabolic pathways, including cell differentiation, metabolism of lipids and inflammation. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 86-91 21563652-6 2011 Pioglitazone (PGZ) is an agonist of peroxisome proliferator-activated receptor gamma (PPARg), itself a member of the nuclear receptor superfamily, responsible for the modulation of a number of metabolic pathways, including cell differentiation, metabolism of lipids and inflammation. Pioglitazone 14-17 peroxisome proliferator-activated receptor gamma Rattus norvegicus 36-84 21563652-6 2011 Pioglitazone (PGZ) is an agonist of peroxisome proliferator-activated receptor gamma (PPARg), itself a member of the nuclear receptor superfamily, responsible for the modulation of a number of metabolic pathways, including cell differentiation, metabolism of lipids and inflammation. Pioglitazone 14-17 peroxisome proliferator-activated receptor gamma Rattus norvegicus 86-91 21373272-4 2011 The protective effect of PPAR-gamma ligands, pioglitazone or 15-deoxy-Delta(12,14)-prostaglandin J(2), on gastric ischemia-reperfusion injury was reversed by the co-administration with PPAR-gamma antagonist. Pioglitazone 45-57 peroxisome proliferator-activated receptor gamma Rattus norvegicus 25-35 21373272-4 2011 The protective effect of PPAR-gamma ligands, pioglitazone or 15-deoxy-Delta(12,14)-prostaglandin J(2), on gastric ischemia-reperfusion injury was reversed by the co-administration with PPAR-gamma antagonist. Pioglitazone 45-57 peroxisome proliferator-activated receptor gamma Rattus norvegicus 185-195 21147840-4 2011 In the current study, we determined that pioglitazone (PIO), a PPAR-gamma agonist, decreases polycystic kidney and liver disease progression in the polycystic kidney rat, an orthologous model of human ARPKD. Pioglitazone 41-53 peroxisome proliferator-activated receptor gamma Rattus norvegicus 63-73 21147840-4 2011 In the current study, we determined that pioglitazone (PIO), a PPAR-gamma agonist, decreases polycystic kidney and liver disease progression in the polycystic kidney rat, an orthologous model of human ARPKD. Pioglitazone 55-58 peroxisome proliferator-activated receptor gamma Rattus norvegicus 63-73 21125653-4 2011 Adult rats treated with pioglitazone, a specific ligand of PPARgamma, had elevated numbers of proliferating progenitor cells in the subventricular zone and the rostral migratory stream. Pioglitazone 24-36 peroxisome proliferator-activated receptor gamma Rattus norvegicus 59-68 21034856-2 2011 OBJECTIVE: The purpose of this study was to test the hypothesis that atrial fibrosis and enhanced vulnerability to AF evoked by pressure overload can be attenuated by pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, via suppression of inflammatory profibrotic signals. Pioglitazone 167-179 peroxisome proliferator-activated receptor gamma Rattus norvegicus 183-231 21532159-2 2011 Losartan (angiotensin II receptor blocker, ARB) and pioglitazone (peroxisome proliferator-activated receptor-gamma, PPARgamma agonist) have been shown to confer renoprotection. Pioglitazone 52-64 peroxisome proliferator-activated receptor gamma Rattus norvegicus 66-114 21532159-2 2011 Losartan (angiotensin II receptor blocker, ARB) and pioglitazone (peroxisome proliferator-activated receptor-gamma, PPARgamma agonist) have been shown to confer renoprotection. Pioglitazone 52-64 peroxisome proliferator-activated receptor gamma Rattus norvegicus 116-125 21532147-2 2011 In the present study, we investigated the effects of pioglitazone, a peroxisome proliferator activated receptor gamma (PPARgamma) agonist, on AGE-induced rat VSMC growth and the underlying mechanism. Pioglitazone 53-65 peroxisome proliferator-activated receptor gamma Rattus norvegicus 119-128 21532147-4 2011 Pretreatment of pioglitazone not only prevented the down-regulation of PPARgamma, but inhibited VSMC proliferation and prevented S-phase entry of cell via a G0-G1 block in the presence of AGEs. Pioglitazone 16-28 peroxisome proliferator-activated receptor gamma Rattus norvegicus 71-80 21532147-8 2011 Collectively, these results suggest that pioglitazone inhibits AGE-induced VSMC proliferation via increasing PPARgamma expression and inhibiting ROS/ERK1/2 signaling pathway. Pioglitazone 41-53 peroxisome proliferator-activated receptor gamma Rattus norvegicus 109-118 20505521-8 2010 Pioglitazone (PPAR gamma agonist, 10 microM) abolished the CSA-induced attenuation of carbachol responses, an effect that was not manifest in presence of GW9662 or l-NAME. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 14-24 20495845-0 2010 PPARgamma agonist pioglitazone inhibits microglia inflammation by blocking p38 mitogen-activated protein kinase signaling pathways. Pioglitazone 18-30 peroxisome proliferator-activated receptor gamma Rattus norvegicus 0-9 20495845-1 2010 OBJECTIVE: The aim of this paper was to investigate the inhibitory effect of peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist pioglitazone on microglia inflammation induced by lipopolysaccharide (LPS). Pioglitazone 146-158 peroxisome proliferator-activated receptor gamma Rattus norvegicus 77-125 20495845-1 2010 OBJECTIVE: The aim of this paper was to investigate the inhibitory effect of peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist pioglitazone on microglia inflammation induced by lipopolysaccharide (LPS). Pioglitazone 146-158 peroxisome proliferator-activated receptor gamma Rattus norvegicus 127-136 20495845-9 2010 Additionally, pioglitazone suppressed PPARgamma loss; enhanced transcriptional activity of PPARgamma; and inhibited nucleus-export of PPARgamma in microglia induced by LPS. Pioglitazone 14-26 peroxisome proliferator-activated receptor gamma Rattus norvegicus 38-47 20495845-9 2010 Additionally, pioglitazone suppressed PPARgamma loss; enhanced transcriptional activity of PPARgamma; and inhibited nucleus-export of PPARgamma in microglia induced by LPS. Pioglitazone 14-26 peroxisome proliferator-activated receptor gamma Rattus norvegicus 91-100 20495845-9 2010 Additionally, pioglitazone suppressed PPARgamma loss; enhanced transcriptional activity of PPARgamma; and inhibited nucleus-export of PPARgamma in microglia induced by LPS. Pioglitazone 14-26 peroxisome proliferator-activated receptor gamma Rattus norvegicus 91-100 20164119-2 2010 Pioglitazone (PIO), a peroxisome proliferator-activated receptor (PPAR)-gamma agonist, protects against myocardial ischaemia-reperfusion (IR) injury. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 22-77 20164119-2 2010 Pioglitazone (PIO), a peroxisome proliferator-activated receptor (PPAR)-gamma agonist, protects against myocardial ischaemia-reperfusion (IR) injury. Pioglitazone 14-17 peroxisome proliferator-activated receptor gamma Rattus norvegicus 22-77 20164119-6 2010 In H9c2 cells, the effects of PIO and rosiglitazone on miR-29 expression levels were blocked by a selective PPAR-gamma inhibitor GW9662. Pioglitazone 30-33 peroxisome proliferator-activated receptor gamma Rattus norvegicus 108-118 20726985-3 2010 The present study aimed to elucidate the molecular mechanisms underlying the reversal of prostatic enlargement in insulin-resistant rats by the peroxisome proliferator-activated receptor gamma agonist pioglitazone. Pioglitazone 201-213 peroxisome proliferator-activated receptor gamma Rattus norvegicus 144-192 21793336-4 2010 All the animals were divided into 3 groups: I: control group; II: diabetic group; III: diabetes+Pioglitazone (Piog, a PPARgamma ligand) administration group. Pioglitazone 96-108 peroxisome proliferator-activated receptor gamma Rattus norvegicus 118-127 20233219-2 2010 Pioglitazone, a selective peroxisome proliferator-activated receptor (PPAR)gamma agonist, is currently used to manage insulin resistance, but the specific molecular mechanisms activated by PPARgamma are not yet fully understood. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 70-80 20233219-2 2010 Pioglitazone, a selective peroxisome proliferator-activated receptor (PPAR)gamma agonist, is currently used to manage insulin resistance, but the specific molecular mechanisms activated by PPARgamma are not yet fully understood. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 189-198 20695692-2 2010 Pioglitazone, a potent synthetic agonists of PPARgamma, has shown to control neuroinflammation in many nervous system-related disorders. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 45-54 20814070-2 2010 Pioglitazone as an agonist of peroxisome proliferator-activated receptor gamma (PPARgamma) is used as anti-diabetic drug and has additionally gastroprotective activities. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 30-78 20814070-2 2010 Pioglitazone as an agonist of peroxisome proliferator-activated receptor gamma (PPARgamma) is used as anti-diabetic drug and has additionally gastroprotective activities. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 80-89 20189191-2 2010 Because peroxisome proliferator-activated receptor-gamma activator pioglitazone was recently reported to possess pleiotropic protective effects on various organs and tissues, we conducted experiments to test the hypothesis that pioglitazone could prevent graft degeneration, leading to the preservation of vein graft integrity. Pioglitazone 67-79 peroxisome proliferator-activated receptor gamma Rattus norvegicus 8-56 20189191-7 2010 Immunofluorescent staining showed that pioglitazone enhanced peroxisome proliferator-activated receptor-gamma expression in vein grafts at 8 weeks, especially in their intimal side. Pioglitazone 39-51 peroxisome proliferator-activated receptor gamma Rattus norvegicus 61-109 20050918-3 2010 Apoptosis was induced in mature 3T3-L1 adipocytes by treatment with troglitazone, pioglitazone or prostaglandin J2, and could be blocked by the PPARgamma antagonist GW9662. Pioglitazone 82-94 peroxisome proliferator-activated receptor gamma Rattus norvegicus 144-153 20410836-3 2010 We studied in rats the effects of the PPARgamma agonist, pioglitazone, on the regulation of IL-1beta, IL-1ra and IL-1 receptor I (IL-1RI) expression in ischaemic brain after occlusion of the middle cerebral artery for 90 min. Pioglitazone 57-69 peroxisome proliferator-activated receptor gamma Rattus norvegicus 38-47 20599729-4 2010 However, peroxysome-proliferator-activated-receptor-gamma (PPARgamma) agonist pioglitazone significantly (P<0.001) restored S961 induced hyperglycemia (196.73+/-16.32 vs. 126.37+/-27.07 mg/dl) and glucose intolerance (approximately 78%). Pioglitazone 78-90 peroxisome proliferator-activated receptor gamma Rattus norvegicus 9-57 20599729-4 2010 However, peroxysome-proliferator-activated-receptor-gamma (PPARgamma) agonist pioglitazone significantly (P<0.001) restored S961 induced hyperglycemia (196.73+/-16.32 vs. 126.37+/-27.07 mg/dl) and glucose intolerance (approximately 78%). Pioglitazone 78-90 peroxisome proliferator-activated receptor gamma Rattus norvegicus 59-68 20410836-9 2010 In primary cortical neurones, pioglitazone stimulated the IL-1ra production via activation of the PPARbeta/delta, but prevented excitotoxic neuronal injury and death by a PPARgamma-dependent mechanism. Pioglitazone 30-42 peroxisome proliferator-activated receptor gamma Rattus norvegicus 171-180 20566448-0 2010 Pioglitazone, a PPAR-gamma ligand inhibited the nicotinamide-streptozotocin induced sperm abnormalities in type-2 diabetic Wistar rats. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 16-26 20566448-2 2010 Pioglitazone (PIO), a PPAR-gamma ligand is known to possess the antioxidant property however, its role on the oxidative stress mediated germinal damage in Type-2 diabetes mellitus (T2DM) is poorly studies in the literature. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 22-32 20566448-2 2010 Pioglitazone (PIO), a PPAR-gamma ligand is known to possess the antioxidant property however, its role on the oxidative stress mediated germinal damage in Type-2 diabetes mellitus (T2DM) is poorly studies in the literature. Pioglitazone 14-17 peroxisome proliferator-activated receptor gamma Rattus norvegicus 22-32 20107770-3 2010 Thiazolidinediones (TZDs) such as pioglitazone activate PPARgamma and are clinically used as antidiabetics. Pioglitazone 34-46 peroxisome proliferator-activated receptor gamma Rattus norvegicus 56-65 19942298-6 2010 These results suggest that PPAR-gamma agonists, 15d-PGJ(2) and pioglitazone, had the anti-inflammatory effects. Pioglitazone 63-75 peroxisome proliferator-activated receptor gamma Rattus norvegicus 27-37 19858066-0 2010 Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat. Pioglitazone 11-23 peroxisome proliferator-activated receptor gamma Rattus norvegicus 27-75 19858066-2 2010 Some PPARgamma agonists, such as pioglitazone, and dual PPARgamma/PPARalpha agonists, such as muraglitazar, induced urothelial bladder tumors in rats but not in mice. Pioglitazone 33-45 peroxisome proliferator-activated receptor gamma Rattus norvegicus 5-14 19858066-6 2010 PPARgamma agonists (pioglitazone and troglitazone) in vitro reduced rat urothelial cell proliferation and induced uroplakin synthesis, a specific differentiation marker in urothelial cells. Pioglitazone 20-32 peroxisome proliferator-activated receptor gamma Rattus norvegicus 0-9 19331671-0 2009 Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)alpha agonist fenofibrate and the PPARgamma agonist pioglitazone. Pioglitazone 135-147 peroxisome proliferator-activated receptor gamma Rattus norvegicus 117-126 19333142-3 2009 Several studies have implicated the peroxisome proliferator-activated receptor gamma agonists rosiglitazone and pioglitazone in inflammatory events. Pioglitazone 112-124 peroxisome proliferator-activated receptor gamma Rattus norvegicus 36-84 19174742-0 2009 Peroxisome proliferator-activated receptor-gamma ligands 15-deoxy-delta(12,14)-prostaglandin J2 and pioglitazone inhibit hydroxyl peroxide-induced TNF-alpha and lipopolysaccharide-induced CXC chemokine expression in neonatal rat cardiac myocytes. Pioglitazone 100-112 peroxisome proliferator-activated receptor gamma Rattus norvegicus 0-48 19174742-10 2009 The cytoprotection afforded by pioglitazone was attenuated by the PPAR-gamma antagonist GW9662, which failed to affect the beneficial effects afforded by 15d-PGJ2. Pioglitazone 31-43 peroxisome proliferator-activated receptor gamma Rattus norvegicus 66-76 19281808-0 2009 Involvement of glucocorticoid receptor and peroxisome proliferator activated receptor-gamma in pioglitazone mediated chronic gastric ulcer healing in rats. Pioglitazone 95-107 peroxisome proliferator-activated receptor gamma Rattus norvegicus 43-91 19281808-1 2009 Evidences suggest Peroxisome Proliferator Activated Receptor-gamma (PPAR-gamma) ligand, pioglitazone results in the attenuation of gastric mucosal injury. Pioglitazone 88-100 peroxisome proliferator-activated receptor gamma Rattus norvegicus 18-66 19281808-1 2009 Evidences suggest Peroxisome Proliferator Activated Receptor-gamma (PPAR-gamma) ligand, pioglitazone results in the attenuation of gastric mucosal injury. Pioglitazone 88-100 peroxisome proliferator-activated receptor gamma Rattus norvegicus 68-78 19281808-4 2009 Pioglitazone treatment reduced the severity of ulceration, repressed levels of TNF-alpha, IL-1beta and nuclear p65 subunit as well as increased the abundance of PPAR-gamma in gastric mucosa. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 161-171 19281808-6 2009 Administration of pioglitazone reverted back the decreased levels of both PPAR-gamma and glucocorticoid receptor, resulting in their redistribution to the nucleus from the cytosol in course of ulcer healing. Pioglitazone 18-30 peroxisome proliferator-activated receptor gamma Rattus norvegicus 74-112 19281808-8 2009 Co-immunoprecipitation studies further established association of PPAR-gamma with glucocorticoid receptor during ulcer healing which was enhanced following pioglitazone administration. Pioglitazone 156-168 peroxisome proliferator-activated receptor gamma Rattus norvegicus 66-76 19281808-9 2009 Thus, the present study is first of its kind bearing direct relevance to the participation of both PPAR-gamma and glucocorticoid receptor and their physical association in influencing amelioration of inflammatory responses during pioglitazone mediated gastric ulcer healing. Pioglitazone 230-242 peroxisome proliferator-activated receptor gamma Rattus norvegicus 99-137 19800324-4 2009 In the present study, we examined the effects of a PPARgamma agonist, pioglitazone, on glucose metabolism in cultured rat neurons and astroglia. Pioglitazone 70-82 peroxisome proliferator-activated receptor gamma Rattus norvegicus 51-60 19800324-11 2009 These actions of pioglitazone were not inhibited by 2-chloro-5-nitrobenzanilide (GW9662), a potent antagonist of PPARgamma, and were not mimicked by N-(2-benzoylphenyl)-O-[2-(methyl-2-pyridinylamino)ethyl]-l-tyrosine (GW1929), a non-thiazolidinedione PPARgamma agonist. Pioglitazone 17-29 peroxisome proliferator-activated receptor gamma Rattus norvegicus 113-122 19800324-11 2009 These actions of pioglitazone were not inhibited by 2-chloro-5-nitrobenzanilide (GW9662), a potent antagonist of PPARgamma, and were not mimicked by N-(2-benzoylphenyl)-O-[2-(methyl-2-pyridinylamino)ethyl]-l-tyrosine (GW1929), a non-thiazolidinedione PPARgamma agonist. Pioglitazone 17-29 peroxisome proliferator-activated receptor gamma Rattus norvegicus 251-260 20085125-1 2009 BACKGROUND: The present study was conducted to assess the effect of Pioglitazone, an oral antidiabetic drug with selective PPAR-gamma agonist effect; in a dose of 4 mg/kg B.W. Pioglitazone 68-80 peroxisome proliferator-activated receptor gamma Rattus norvegicus 123-133 19377624-5 2009 Pioglitazone was chosen as agonist of PPAR-gamma and GW9662 used as a specific complete antagonist of PPAR-gamma. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 38-48 19377624-14 2009 Sulindac and agonist of PPAR-Gamma (pioglitazone) could inhibit the formation of ACF, and followed by a decrease of PPAR-gamma. Pioglitazone 36-48 peroxisome proliferator-activated receptor gamma Rattus norvegicus 24-34 19377624-14 2009 Sulindac and agonist of PPAR-Gamma (pioglitazone) could inhibit the formation of ACF, and followed by a decrease of PPAR-gamma. Pioglitazone 36-48 peroxisome proliferator-activated receptor gamma Rattus norvegicus 116-126 19331671-3 2009 The aim of the study was to examine the effect of the PPARalpha agonist fenofibrate (FENO) and the PPARgamma agonist pioglitazone (PIO) on bone in intact female rats. Pioglitazone 117-129 peroxisome proliferator-activated receptor gamma Rattus norvegicus 99-108 19088251-0 2009 Adiponectin translation is increased by the PPARgamma agonists pioglitazone and omega-3 fatty acids. Pioglitazone 63-75 peroxisome proliferator-activated receptor gamma Rattus norvegicus 44-53 19088251-10 2009 Together, these data suggest that pioglitazone and the fish oils DHA or EPA are PPARgamma agonists in adipocytes with regard to adiponectin expression, and the predominant mode of adiponectin stimulation is via an increase in translation. Pioglitazone 34-46 peroxisome proliferator-activated receptor gamma Rattus norvegicus 80-89 19088251-4 2009 Overnight treatment of rat adipocytes with pioglitazone, docosahexaenoic acid (DHA), or eicosapentaenoic acid (EPA) triggered a twofold increase in the synthesis and secretion of HMW adiponectin, and this increase was blocked by the addition of PPARgamma inhibitor GW-9662. Pioglitazone 43-55 peroxisome proliferator-activated receptor gamma Rattus norvegicus 245-254 18759864-0 2008 Pioglitazone inhibits homocysteine-induced migration of vascular smooth muscle cells through a peroxisome proliferator-activated receptor gamma-independent mechanism. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 95-143 19878073-11 2009 CONCLUSION: Visfatin is preferentially produced by visceral fat and peroxisome proliferator-activated receptor-gamma agonist ameliorates the development of insulin resistance in HF-fed rats with a major decrease in visfatin expression, the effect of pioglitazone on visfatin in HF-fed rats is dependent on glucose and lipid metabolism in the animals. Pioglitazone 250-262 peroxisome proliferator-activated receptor gamma Rattus norvegicus 68-116 18931027-2 2008 In the rat, the peroxisome proliferator-activated receptor-gamma agonist pioglitazone (Pio) limits IS, upregulates and activates cPLA2 and COX2, and increases myocardial 6-keto-PGF1alpha levels without activating eNOS and iNOS. Pioglitazone 73-85 peroxisome proliferator-activated receptor gamma Rattus norvegicus 16-64 18931027-2 2008 In the rat, the peroxisome proliferator-activated receptor-gamma agonist pioglitazone (Pio) limits IS, upregulates and activates cPLA2 and COX2, and increases myocardial 6-keto-PGF1alpha levels without activating eNOS and iNOS. Pioglitazone 87-90 peroxisome proliferator-activated receptor gamma Rattus norvegicus 16-64 19439812-6 2009 In contrast, pioglitazone (PPARgamma agonist) had no effect on the content of fatty acid transporters (FAT/CD36, FABPpm and FATP-1) as well as the content of liver lipid fractions with the exception for triacylglycerols, which have been reduced significantly (-89%, p<0.05). Pioglitazone 13-25 peroxisome proliferator-activated receptor gamma Rattus norvegicus 27-36 18973594-3 2008 Pioglitazone, a high-affinity PPARgamma ligand, was infused intracerebroventricularly (i.c.v.) Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 30-39 18973594-6 2008 Pioglitazone augmented the ischaemia-induced upregulation of PPARgamma at both time points. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 61-70 18388116-3 2008 METHODS: In the present study, we investigated the effect and molecular mechanism of the PPARgamma agonist, pioglitazone, on the progression of diabetic nephropathy in type 2 diabetic rats. Pioglitazone 108-120 peroxisome proliferator-activated receptor gamma Rattus norvegicus 89-98 19051726-5 2008 A PPARgamma ligand, pioglitazone, which was reported to inhibit OPN gene expression in vitro, attenuated hypoxia-induced increase in lung OPN gene and pulmonary vascular remodeling in rats. Pioglitazone 20-32 peroxisome proliferator-activated receptor gamma Rattus norvegicus 2-11 18987433-12 2008 The present study demonstrated that pioglitazone causes PPAR-gamma-independent relaxation. Pioglitazone 36-48 peroxisome proliferator-activated receptor gamma Rattus norvegicus 56-66 18490130-0 2008 Pioglitazone, a PPARgamma ligand, suppresses NFkappaB activation through inhibition of IkappaB kinase activation in cerulein-treated AR42J cells. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 16-25 18388116-10 2008 In cultured mesangial cells, pioglitazone-activated endogenous PPARgamma transcriptional activity and abolished high glucose-induced collagen production. Pioglitazone 29-41 peroxisome proliferator-activated receptor gamma Rattus norvegicus 63-72 18387855-10 2008 PERSPECTIVE: PPAR-gamma receptor agonists such as rosiglitazone and pioglitazone are approved as insulin sensitizers by the United States Food and Drug Administration. Pioglitazone 68-80 peroxisome proliferator-activated receptor gamma Rattus norvegicus 13-23 18199331-1 2008 BACKGROUND: Rosiglitazone and pioglitazone are high-affinity peroxisome proliferator-activated receptor (PPAR)-gamma agonists with potent anti-diabetic properties and potential anti-inflammatory effects. Pioglitazone 30-42 peroxisome proliferator-activated receptor gamma Rattus norvegicus 61-116 18565023-5 2008 Further, the effect of the PPARgamma agonist, pioglitazone, on liver regeneration (PH + PGZ group) was evaluated by proliferating cell nuclear antigen labeling index, relative liver weight, and expression of cell-cycle regulators. Pioglitazone 46-58 peroxisome proliferator-activated receptor gamma Rattus norvegicus 27-36 18207323-2 2008 Pioglitazone, an agonist of peroxisome proliferator activated receptor-gamma (PPAR-gamma), can prevent these deficits and protect dopaminergic neurons. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 28-76 18207323-2 2008 Pioglitazone, an agonist of peroxisome proliferator activated receptor-gamma (PPAR-gamma), can prevent these deficits and protect dopaminergic neurons. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 78-88 18158350-1 2008 The effect of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on hypertensive cardiovascular injury is unknown. Pioglitazone 14-26 peroxisome proliferator-activated receptor gamma Rattus norvegicus 30-78 18199331-13 2008 Rosiglitazone 10 mg/kg/day or pioglitazone 30 mg/kg/day increased the expression of PPAR-gamma and adiponectin in adipose tissue, confirming that they were activating PPAR-gamma in inflammatory conditions, although an increase in fat mass percentage was observed for the most anti-arthritic dose. Pioglitazone 30-42 peroxisome proliferator-activated receptor gamma Rattus norvegicus 84-94 18199331-13 2008 Rosiglitazone 10 mg/kg/day or pioglitazone 30 mg/kg/day increased the expression of PPAR-gamma and adiponectin in adipose tissue, confirming that they were activating PPAR-gamma in inflammatory conditions, although an increase in fat mass percentage was observed for the most anti-arthritic dose. Pioglitazone 30-42 peroxisome proliferator-activated receptor gamma Rattus norvegicus 167-177 17662078-11 2007 CONCLUSIONS: Pioglitazone ameliorated ageing-related CVOD, possibly by a PPARgamma-mediated inhibition of Rho-kinase and not by a protective effect on the corporal smooth muscle. Pioglitazone 13-25 peroxisome proliferator-activated receptor gamma Rattus norvegicus 73-82 18047631-16 2008 4 Our data demonstrate that the PPAR-gamma agonists 15d-PGJ2 and pioglitazone attenuate AngII-mediated collagen type I expression in adventitial fibroblasts, which may be mediated by the modulation of ROS release and the redox-sensitive transcription factor NF-kappaB. Pioglitazone 65-77 peroxisome proliferator-activated receptor gamma Rattus norvegicus 32-42 17995925-1 2008 Pioglitazone, one of thiazolidinediones, a peroxisome proliferator-activated receptor (PPAR)-gamma ligand, is known to have beneficial effects on macrovascular complications in diabetes, but the effect on diabetic neuropathy is not well addressed. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 43-98 17410441-6 2007 Compared with telmisartan, the peroxisome proliferator-activated receptor-gamma agonist pioglitazone attenuated hepatic steatosis and fibrosis of the liver to a similar degree. Pioglitazone 88-100 peroxisome proliferator-activated receptor gamma Rattus norvegicus 31-79 17449904-0 2007 Suppression of N-nitrosobis(2-oxopropyl)amine-induced pancreatic carcinogenesis in hamsters by pioglitazone, a ligand of peroxisome proliferator-activated receptor gamma. Pioglitazone 95-107 peroxisome proliferator-activated receptor gamma Rattus norvegicus 121-169 17592505-5 2007 KEY RESULTS: Peroxisome proliferator-activated receptor gamma activators inhibited the metabolism of the endocannabinoid anandamide in rat brain homogenates with an order of potency MCC-555 > indomethacin approximately ciglitazone approximately 15-deoxy-Delta(12,14)-prostaglandin J(2) approximately pioglitazone > rosiglitazone > troglitazone. Pioglitazone 303-315 peroxisome proliferator-activated receptor gamma Rattus norvegicus 13-61 17433295-0 2007 The PPAR gamma agonist Pioglitazone improves anatomical and locomotor recovery after rodent spinal cord injury. Pioglitazone 23-35 peroxisome proliferator-activated receptor gamma Rattus norvegicus 4-14 17582756-0 2007 The PPARgamma agonist pioglitazone inhibits early neoplastic occurrence in the rat liver. Pioglitazone 22-34 peroxisome proliferator-activated receptor gamma Rattus norvegicus 4-13 17582756-4 2007 We evaluated the preventive effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the induction of early carcinogenic events. Pioglitazone 39-51 peroxisome proliferator-activated receptor gamma Rattus norvegicus 55-103 17433295-3 2007 Therefore, we examined the efficacy of the PPARgamma agonist Pioglitazone in a rodent SCI model. Pioglitazone 61-73 peroxisome proliferator-activated receptor gamma Rattus norvegicus 43-52 17343847-0 2007 Antinociceptive and antiedematogenic activities of fenofibrate, an agonist of PPAR alpha, and pioglitazone, an agonist of PPAR gamma. Pioglitazone 94-106 peroxisome proliferator-activated receptor gamma Rattus norvegicus 122-132 17538229-2 2007 The administration of pioglitazone, a PPARgamma agonist, to Zucker obese rats greatly improved their insulin sensitivity. Pioglitazone 22-34 peroxisome proliferator-activated receptor gamma Rattus norvegicus 38-47 17349927-1 2007 The objectives of this study were to determine the effects of chronic treatment with pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the impaired endothelium-dependent relaxation seen in aortas from established streptozotocin (STZ)-induced diabetic rats, and to identify some of the molecular mechanisms involved. Pioglitazone 85-97 peroxisome proliferator-activated receptor gamma Rattus norvegicus 101-149 17461502-1 2007 AIM: To determine the effect of pioglitazone, a specific peroxisome proliferator-activated receptor-gamma (PPARgamma) ligand, on development of severe acute pancreatitis (SAP) and expression of nuclear factor-kappa B (NF-kappaB) and intercellular adhesion molecule-1 (ICAM-1) in the pancreas. Pioglitazone 32-44 peroxisome proliferator-activated receptor gamma Rattus norvegicus 57-105 17461502-1 2007 AIM: To determine the effect of pioglitazone, a specific peroxisome proliferator-activated receptor-gamma (PPARgamma) ligand, on development of severe acute pancreatitis (SAP) and expression of nuclear factor-kappa B (NF-kappaB) and intercellular adhesion molecule-1 (ICAM-1) in the pancreas. Pioglitazone 32-44 peroxisome proliferator-activated receptor gamma Rattus norvegicus 107-116 17254027-4 2007 We tested the hypothesis that celecoxib (Celebrex, COX-2 inhibitor) or pioglitazone (Actos, PPAR-gamma agonist) will reduce the LPS-induced inflammatory response, spare mitochondrial bioenergetics, and improve nigral dopaminergic neuronal survival. Pioglitazone 71-83 peroxisome proliferator-activated receptor gamma Rattus norvegicus 92-102 17259076-6 2007 Therefore, the aim of our study was to examine the effects of pioglitazone, a selective PPARgamma agonist, on the content of CER and its metabolites and on the activity of key enzymes of CER metabolism in the heart. Pioglitazone 62-74 peroxisome proliferator-activated receptor gamma Rattus norvegicus 88-97 17167171-10 2007 Pretreatment with a PPARgamma antagonist, 2-chloro-5-nitro-N-phenyl-benzamide (GW9662), prevented the neuroprotection induced by pioglitazone. Pioglitazone 129-141 peroxisome proliferator-activated receptor gamma Rattus norvegicus 20-29 17141574-0 2007 Long-term effects of a PPAR-gamma agonist, pioglitazone, on neointimal hyperplasia and endothelial regrowth in insulin resistant rats. Pioglitazone 43-55 peroxisome proliferator-activated receptor gamma Rattus norvegicus 23-33 17141574-2 2007 PPAR-gamma agonists like pioglitazone decrease insulin resistance and have been shown to reduce neointimal hyperplasia in the short-term. Pioglitazone 25-37 peroxisome proliferator-activated receptor gamma Rattus norvegicus 0-10 17189061-0 2007 Administration of the peroxisomal proliferator-activated receptor gamma agonist pioglitazone during fractionated brain irradiation prevents radiation-induced cognitive impairment. Pioglitazone 80-92 peroxisome proliferator-activated receptor gamma Rattus norvegicus 22-71 17189061-1 2007 PURPOSE: We hypothesized that administration of the anti-inflammatory peroxisomal proliferator-activated receptor gamma (PPARgamma) agonist pioglitazone (Pio) to adult male rats would inhibit radiation-induced cognitive impairment. Pioglitazone 140-152 peroxisome proliferator-activated receptor gamma Rattus norvegicus 70-119 17189061-1 2007 PURPOSE: We hypothesized that administration of the anti-inflammatory peroxisomal proliferator-activated receptor gamma (PPARgamma) agonist pioglitazone (Pio) to adult male rats would inhibit radiation-induced cognitive impairment. Pioglitazone 140-152 peroxisome proliferator-activated receptor gamma Rattus norvegicus 121-130 17189061-1 2007 PURPOSE: We hypothesized that administration of the anti-inflammatory peroxisomal proliferator-activated receptor gamma (PPARgamma) agonist pioglitazone (Pio) to adult male rats would inhibit radiation-induced cognitive impairment. Pioglitazone 154-157 peroxisome proliferator-activated receptor gamma Rattus norvegicus 70-119 17189061-1 2007 PURPOSE: We hypothesized that administration of the anti-inflammatory peroxisomal proliferator-activated receptor gamma (PPARgamma) agonist pioglitazone (Pio) to adult male rats would inhibit radiation-induced cognitive impairment. Pioglitazone 154-157 peroxisome proliferator-activated receptor gamma Rattus norvegicus 121-130 17235413-1 2006 Pioglitazone, one of the synthetic peroxisome proliferator-activated receptor (PPARgamma) agonists, has been found to inhibit inflammatory response. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 79-88 17161347-2 2006 Pioglitazone is an agonist of PPARgamma, capable of reducing chronic inflammation. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 30-39 16835400-0 2006 The PPARgamma agonist pioglitazone modifies the vascular sodium-angiotensin II relationship in insulin-resistant rats. Pioglitazone 22-34 peroxisome proliferator-activated receptor gamma Rattus norvegicus 4-13 16835400-12 2006 In conclusion, these data demonstrate that the peroxisome proliferator-activated receptor-gamma agonist pioglitazone modifies the physiological relationship between sodium chloride and the response to ANG II in insulin-resistant rats. Pioglitazone 104-116 peroxisome proliferator-activated receptor gamma Rattus norvegicus 47-95 17356310-0 2007 Effect of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on ischemia-reperfusion injury in rats. Pioglitazone 10-22 peroxisome proliferator-activated receptor gamma Rattus norvegicus 26-74 17356310-8 2007 In addition, acute treatment with pioglitazone dose-dependently increased PPARgamma expression and decreased MMP-2 expression at protein and mRNA levels. Pioglitazone 34-46 peroxisome proliferator-activated receptor gamma Rattus norvegicus 74-83 17235413-9 2006 The effect of pioglitazone might be associated with PPARgamma activation and the consequent antiinflammatory function in prevention and treatment of cardiac hypertrophy. Pioglitazone 14-26 peroxisome proliferator-activated receptor gamma Rattus norvegicus 52-61 17235413-8 2006 Furthermore, pioglitazone upregulated the suppressed expression of PPARgamma and attenuated the increased IL-1beta and IL-6 expression. Pioglitazone 13-25 peroxisome proliferator-activated receptor gamma Rattus norvegicus 67-76 21162229-7 2006 CONCLUSION: Pioglitazone and 15d-PGJ2, as the activators of PPARgamma, inhibit proliferation of CNM from neonatal rats, the effect may be related to the activation of PPARgamma. Pioglitazone 12-24 peroxisome proliferator-activated receptor gamma Rattus norvegicus 60-69 16770015-6 2006 In primary cortical neurons expressing the PPARgamma, pioglitazone suppressed COX-2 expression in response to oxidative stress. Pioglitazone 54-66 peroxisome proliferator-activated receptor gamma Rattus norvegicus 43-52 16687628-0 2006 Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-gamma agonist: molecular mechanism of the antiproteinuric effect of pioglitazone. Pioglitazone 157-169 peroxisome proliferator-activated receptor gamma Rattus norvegicus 46-94 16687628-1 2006 The renoprotective potential of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist pioglitazone was explored in an immune model of progressive nephropathy, passive Heymann nephritis (PHN), compared with that of an angiotensin II receptor antagonist, taken as standard therapy for renoprotection. Pioglitazone 106-118 peroxisome proliferator-activated receptor gamma Rattus norvegicus 86-96 17004929-2 2006 Recently, we found that the peroxisome proliferator-activated receptor-gamma (PPARgamma) agonists troglitazone and pioglitazone reduce injury and inflammation in a rat model of transient cerebral ischemia. Pioglitazone 115-127 peroxisome proliferator-activated receptor gamma Rattus norvegicus 28-76 17004929-2 2006 Recently, we found that the peroxisome proliferator-activated receptor-gamma (PPARgamma) agonists troglitazone and pioglitazone reduce injury and inflammation in a rat model of transient cerebral ischemia. Pioglitazone 115-127 peroxisome proliferator-activated receptor gamma Rattus norvegicus 78-87 21162229-7 2006 CONCLUSION: Pioglitazone and 15d-PGJ2, as the activators of PPARgamma, inhibit proliferation of CNM from neonatal rats, the effect may be related to the activation of PPARgamma. Pioglitazone 12-24 peroxisome proliferator-activated receptor gamma Rattus norvegicus 167-176 15993383-6 2005 Treatment of ZDF rats with PPARgamma agonist pioglitazone decreased serum glucose and VEGF (both p <0.01). Pioglitazone 45-57 peroxisome proliferator-activated receptor gamma Rattus norvegicus 27-36 16306807-2 2005 Pioglitazone, a thiazolidinedione and PPARgamma receptor agonist used in Type II diabetes treatment, has been shown to activate these kinase cascades. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 38-47 16266488-8 2005 CONCLUSIONS: Activating PPARgamma in VSMCs, pioglitazone may play a role in anti atherosclerosis. Pioglitazone 44-56 peroxisome proliferator-activated receptor gamma Rattus norvegicus 24-33 16580578-8 2006 Moreover, the finding that pioglitazone was also efficient in preventing the increase in oxidative stress in SMCs treated with high insulin combined with high glucose concentrations supports the hypothesis that the activation of PPAR-gamma activity can counteract the oxidative stress that seems to be implicated in the development of hypertension and insulin resistance. Pioglitazone 27-39 peroxisome proliferator-activated receptor gamma Rattus norvegicus 229-239 16419161-0 2005 Pioglitazone, a specific ligand of peroxisome proliferator-activated receptor-gamma, protects pancreas against acute cerulein-induced pancreatitis. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 35-83 16419161-1 2005 AIM: To determine the effect of pioglitazone, a specific peroxisome proliferator-activated receptor-gamma (PPARgamma) ligand, on the development of acute pancreatitis (AP) and on the expression of heat shock protein 70 (HSP70) in the pancreas. Pioglitazone 32-44 peroxisome proliferator-activated receptor gamma Rattus norvegicus 57-105 16419161-1 2005 AIM: To determine the effect of pioglitazone, a specific peroxisome proliferator-activated receptor-gamma (PPARgamma) ligand, on the development of acute pancreatitis (AP) and on the expression of heat shock protein 70 (HSP70) in the pancreas. Pioglitazone 32-44 peroxisome proliferator-activated receptor gamma Rattus norvegicus 107-116 15698832-0 2005 Pioglitazone, a peroxisome proliferator-activated receptor gamma activator, ameliorates experimental autoimmune myocarditis by modulating Th1/Th2 balance. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 16-64 16085455-0 2005 The peroxisome proliferator-activated receptor-gamma agonist, pioglitazone, inhibits fat accumulation and fibrosis in the livers of rats fed a choline-deficient, l-amino acid-defined diet. Pioglitazone 62-74 peroxisome proliferator-activated receptor gamma Rattus norvegicus 4-52 16085455-2 2005 The aim of this study was to evaluate if a peroxisome proliferator-activated receptor (PPAR)-gamma agonist, pioglitazone (PGZ), could ameliorate CDAA diet-induced fatty liver and cirrhosis. Pioglitazone 108-120 peroxisome proliferator-activated receptor gamma Rattus norvegicus 43-98 16085455-2 2005 The aim of this study was to evaluate if a peroxisome proliferator-activated receptor (PPAR)-gamma agonist, pioglitazone (PGZ), could ameliorate CDAA diet-induced fatty liver and cirrhosis. Pioglitazone 122-125 peroxisome proliferator-activated receptor gamma Rattus norvegicus 43-98 16029218-0 2005 The intracerebral application of the PPARgamma-ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain. Pioglitazone 54-66 peroxisome proliferator-activated receptor gamma Rattus norvegicus 37-46 16029218-2 2005 application of pioglitazone, a selective ligand of the peroxisome proliferator-activated receptor gamma (PPARgamma) in the rat brain after ischaemia. Pioglitazone 15-27 peroxisome proliferator-activated receptor gamma Rattus norvegicus 55-103 16029218-2 2005 application of pioglitazone, a selective ligand of the peroxisome proliferator-activated receptor gamma (PPARgamma) in the rat brain after ischaemia. Pioglitazone 15-27 peroxisome proliferator-activated receptor gamma Rattus norvegicus 105-114 16080818-10 2005 (2) In a dose-dependent manner, the expressions of Bax and Caspase-3 were depressed, while the expression of Bcl-2, PPARgamma protein and PPARgamma mRNA were enhanced by pioglitazone. Pioglitazone 170-182 peroxisome proliferator-activated receptor gamma Rattus norvegicus 116-125 16080818-10 2005 (2) In a dose-dependent manner, the expressions of Bax and Caspase-3 were depressed, while the expression of Bcl-2, PPARgamma protein and PPARgamma mRNA were enhanced by pioglitazone. Pioglitazone 170-182 peroxisome proliferator-activated receptor gamma Rattus norvegicus 138-147 16080818-13 2005 CONCLUSIONS: Pioglitazone could protect the heart from I/R injury evidenced by the improvement in the expression of PPARgamma at the levels of protein and mRNA after pioglitazone administrated, and by the decrease in the apoptotic cardiomyocytes. Pioglitazone 13-25 peroxisome proliferator-activated receptor gamma Rattus norvegicus 116-125 16080818-13 2005 CONCLUSIONS: Pioglitazone could protect the heart from I/R injury evidenced by the improvement in the expression of PPARgamma at the levels of protein and mRNA after pioglitazone administrated, and by the decrease in the apoptotic cardiomyocytes. Pioglitazone 166-178 peroxisome proliferator-activated receptor gamma Rattus norvegicus 116-125 15842776-1 2005 AIM: To investigate the effect of the peroxisome proliferator-activator receptor (PPAR)-gamma agonist, pioglitazone, on insulin resistance in low-dose streptozotocin and high sucrose-fat diet induced obese rats. Pioglitazone 103-115 peroxisome proliferator-activated receptor gamma Rattus norvegicus 38-93 15737646-0 2005 Pioglitazone reverses down-regulation of cardiac PPARgamma expression in Zucker diabetic fatty rats. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 49-58 15737646-3 2005 Therefore, we analyzed cardiac gene expression, metabolic control, and cardiac glucose uptake in male Zucker diabetic fatty rats (ZDF fa/fa) and lean ZDF rats (+/+) treated with the high affinity PPARgamma agonist pioglitazone or placebo from 12 to 24 weeks of age. Pioglitazone 214-226 peroxisome proliferator-activated receptor gamma Rattus norvegicus 196-205 15737646-5 2005 Pioglitazone increased body weight and improved metabolic control, cardiac PPARgamma, glut-4, and alpha-MHC expression levels in diabetic ZDF rats. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 75-84 15769458-0 2005 Pioglitazone, a PPARgamma agonist, restores endothelial function in aorta of streptozotocin-induced diabetic rats. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 16-25 15769458-1 2005 OBJECTIVE: To study the effect of pioglitazone (a PPAR gamma agonist) treatment on blood pressure, endothelial function, and oxidative stress in streptozotocin (STZ)-induced diabetic rats. Pioglitazone 34-46 peroxisome proliferator-activated receptor gamma Rattus norvegicus 50-60 15734860-0 2005 Pioglitazone induces vascular smooth muscle cell apoptosis through a peroxisome proliferator-activated receptor-gamma, transforming growth factor-beta1, and a Smad2-dependent mechanism. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 69-151 15734860-4 2005 Extracellular TGF-beta1 levels were rapidly increased after treatment with pioglitazone in a peroxisome proliferator-activated receptor (PPAR)-gamma-dependent mechanism because this secretion was blocked by the PPAR-gamma inhibitor GW9662. Pioglitazone 75-87 peroxisome proliferator-activated receptor gamma Rattus norvegicus 93-148 15734860-4 2005 Extracellular TGF-beta1 levels were rapidly increased after treatment with pioglitazone in a peroxisome proliferator-activated receptor (PPAR)-gamma-dependent mechanism because this secretion was blocked by the PPAR-gamma inhibitor GW9662. Pioglitazone 75-87 peroxisome proliferator-activated receptor gamma Rattus norvegicus 211-221 15734860-6 2005 According to our results, we propose that the apoptotic effect of pioglitazone on VSMC depends on the following sequence: PPAR-gamma activation, TGF-beta1 release, and selective phospho-Smad2 nuclear recruitment. Pioglitazone 66-78 peroxisome proliferator-activated receptor gamma Rattus norvegicus 122-132 15721625-1 2005 PURPOSE: To determine the efficacy of the peroxisome proliferator-activated receptor gamma agonist, pioglitazone, in inhibiting corneal neovascularization. Pioglitazone 100-112 peroxisome proliferator-activated receptor gamma Rattus norvegicus 42-90 15618443-3 2005 METHODS: In 2 groups of rats, 90 minutes of middle cerebral artery (MCA) occlusion was followed by 1 day of reperfusion, with 1 group receiving pioglitazone (a PPARgamma agonist) starting 72 hours before MCA occlusion (MCAO) and continuing through the day of occlusion, whereas the other group received vehicle only. Pioglitazone 144-156 peroxisome proliferator-activated receptor gamma Rattus norvegicus 160-169 15644937-0 2004 Long-term effects of the PPAR gamma activator pioglitazone on cardiac inflammation in stroke-prone spontaneously hypertensive rats. Pioglitazone 46-58 peroxisome proliferator-activated receptor gamma Rattus norvegicus 25-35 16259750-1 2005 Pioglitazone, a specific ligand for peroxisome proliferator-activated receptor gamma (PPAR-gamma), was recently implicated in the control of inflammatory processes and in the modulation of the expression of various cytokines such as tumor necrosis factor alpha (TNF-alpha), but its role in the mechanism of gastric mucosal integrity has not been studied extensively. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 36-84 16259750-1 2005 Pioglitazone, a specific ligand for peroxisome proliferator-activated receptor gamma (PPAR-gamma), was recently implicated in the control of inflammatory processes and in the modulation of the expression of various cytokines such as tumor necrosis factor alpha (TNF-alpha), but its role in the mechanism of gastric mucosal integrity has not been studied extensively. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 86-96 16259750-13 2005 We conclude that (1) pioglitazone exerts a potent gastroprotective and hyperaemic actions on the stomach involving endogenous PG and NO and attenuation of the expression and release of proinflammatory cytokines TNF-alpha and IL-1beta, and (2) PPAR-gamma ligand accelerates ulcer healing, possibly due to the enhancement in angiogenesis at ulcer margin. Pioglitazone 21-33 peroxisome proliferator-activated receptor gamma Rattus norvegicus 243-253 15452359-0 2005 Novel PPARgamma agonists GI 262570, GW 7845, GW 1929, and pioglitazone decrease calcium channel function and myogenic tone in rat mesenteric arteries. Pioglitazone 58-70 peroxisome proliferator-activated receptor gamma Rattus norvegicus 6-15 15364003-2 2004 In the present study, we investigated the effect of pioglitazone, a potent PPAR-gamma ligand, on the endotoxin-induced reduction of hepatic drug-metabolizing enzyme activity and on the down-regulation of the expression of hepatic cytochrome P450 (CYP) 3A2 and CYP2C11 proteins in rats. Pioglitazone 52-64 peroxisome proliferator-activated receptor gamma Rattus norvegicus 75-85 15052691-14 2004 CONCLUSION: PPARgamma agonist pioglitazone greatly retards the progression of rat hepatic fibrosis induced by CCl(4) through inhibition of HSC activation and amelioration of hepatocyte necroinflammation in rats. Pioglitazone 30-42 peroxisome proliferator-activated receptor gamma Rattus norvegicus 12-21 15037267-0 2004 Protective effects of preischemic treatment with pioglitazone, a peroxisome proliferator-activated receptor-gamma ligand, on lung ischemia-reperfusion injury in rats. Pioglitazone 49-61 peroxisome proliferator-activated receptor gamma Rattus norvegicus 65-113 15037267-4 2004 We examined the effects of pioglitazone, a synthetic ligand of PPAR-gamma, against lung ischemia-reperfusion injury in rats. Pioglitazone 27-39 peroxisome proliferator-activated receptor gamma Rattus norvegicus 63-73 15318101-5 2004 In this study, we investigated the effects of pioglitazone, a ligand for PPAR-gamma, on acute liver injury induced by ethanol and LPS. Pioglitazone 46-58 peroxisome proliferator-activated receptor gamma Rattus norvegicus 73-83 15318101-16 2004 PPAR-gamma mRNA levels were suppressed by ethanol and LPS but recaptured by pioglitazone. Pioglitazone 76-88 peroxisome proliferator-activated receptor gamma Rattus norvegicus 0-10 14988841-2 2004 This study aimed to examine if pioglitazone, an antidiabetic reagent serving as a ligand of peroxisome proliferator-activated receptor gamma (PPAR gamma), could prevent alcoholic fatty liver. Pioglitazone 31-43 peroxisome proliferator-activated receptor gamma Rattus norvegicus 92-140 14988841-2 2004 This study aimed to examine if pioglitazone, an antidiabetic reagent serving as a ligand of peroxisome proliferator-activated receptor gamma (PPAR gamma), could prevent alcoholic fatty liver. Pioglitazone 31-43 peroxisome proliferator-activated receptor gamma Rattus norvegicus 142-152 14638618-4 2004 Pioglitazone treatment increased PPARgamma expression and activity in OP rats, suggesting a possible direct ligand-related effect of pioglitazone. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 33-42 28443766-0 2003 Pioglitazone, a Specific Ligand of the Peroxisome Proliferator-Activated Receptor Gamma Reduces Gastric Mucosal Injury Induced by Ischaemia/Reperfusion in Rat. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 39-87 12805475-0 2003 Prevention of ethanol-induced liver injury in rats by an agonist of peroxisome proliferator-activated receptor-gamma, pioglitazone. Pioglitazone 118-130 peroxisome proliferator-activated receptor gamma Rattus norvegicus 68-116 12805475-3 2003 This study was intended to determine whether pioglitazone, a PPAR-gamma agonist, could prevent alcohol-induced liver injury. Pioglitazone 45-57 peroxisome proliferator-activated receptor gamma Rattus norvegicus 61-71 12795455-2 2003 The present study was designed to investigate the effect of the specific PPARgamma ligand, pioglitazone, on the mucosal lesions induced by ischaemia and reperfusion (I/R) in rats. Pioglitazone 91-103 peroxisome proliferator-activated receptor gamma Rattus norvegicus 73-82 12486128-4 2003 Incubation of cortical astrocytes with the PPAR gamma thiazolidinedione (TZD) agonist pioglitazone (Pio) significantly increased glucose consumption in a time- and dose-dependent manner, with maximal increase of 36% observed after 4 h in 30 microm Pio. Pioglitazone 86-98 peroxisome proliferator-activated receptor gamma Rattus norvegicus 43-53 12486128-4 2003 Incubation of cortical astrocytes with the PPAR gamma thiazolidinedione (TZD) agonist pioglitazone (Pio) significantly increased glucose consumption in a time- and dose-dependent manner, with maximal increase of 36% observed after 4 h in 30 microm Pio. Pioglitazone 100-103 peroxisome proliferator-activated receptor gamma Rattus norvegicus 43-53 14691289-0 2003 Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia/reperfusion injury in a rat model. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 16-64 14691289-3 2003 This study examined the effects of the thiazolidinedione peroxisome proliferator-activated receptor-gamma ligand, pioglitazone, in a rat model of MI/R injury. Pioglitazone 114-126 peroxisome proliferator-activated receptor gamma Rattus norvegicus 57-105 14601316-1 2003 OBJECTIVE: To investigate the chemopreventive effects of pioglitazone (exogenous PPAR gamma ligand) on rat colon aberrant crypt foci, a rat carcinogenesis model induced by dimethylhydrazine (DMH), and to compare pioglitazone with sulindac (a NSAID). Pioglitazone 57-69 peroxisome proliferator-activated receptor gamma Rattus norvegicus 81-91 12871756-0 2003 Pioglitazone, a specific ligand of peroxisome proliferator-activated receptor-gamma, accelerates gastric ulcer healing in rat. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 35-83 12871756-2 2003 We determined the effect of the specific PPAR-gamma ligand, pioglitazone (5-40 mg/kg intragastrically), on the healing of acetic-acid gastric ulcers in rats. Pioglitazone 60-72 peroxisome proliferator-activated receptor gamma Rattus norvegicus 41-51 12795455-0 2003 Pioglitazone, a specific ligand of the peroxisome proliferator-activated receptor gamma reduces gastric mucosal injury induced by ischaemia/ reperfusion in rat. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 39-87 14586740-5 2003 Pioglitazone, a PPARgamma activator, mimicked the effect of troglitazone, but bezafibrate, a PPARalpha-activator, did not. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 16-25 28443766-2 2003 The present study was designed to investigate the effect of the specific PPARgamma ligand, pioglitazone, on the mucosal lesions induced by ischaemia and reperfusion (I/R) in rats. Pioglitazone 91-103 peroxisome proliferator-activated receptor gamma Rattus norvegicus 73-82 12411463-4 2002 We examined the effects of pioglitazone (a PPARgamma ligand) in this rat model to determine whether PPARgamma activation with pioglitazone inhibits arteriosclerosis by its indirect effects on metabolic conditions or by direct effects on the cells participating to the pathogenesis of arteriosclerosis. Pioglitazone 126-138 peroxisome proliferator-activated receptor gamma Rattus norvegicus 100-109 12688513-0 2002 Suppression of intestinal ischemia-reperfusion injury by a specific peroxisome proliferator-activated receptor-gamma ligand, pioglitazone, in rats. Pioglitazone 125-137 peroxisome proliferator-activated receptor gamma Rattus norvegicus 68-116 12193046-3 2002 We investigated the effects of the thiazolidinediones troglitazone and pioglitazone, activators of PPAR gamma, on cardiac hypertrophy due to pressure overload provoked by abdominal aortic banding (AB) in rats. Pioglitazone 71-83 peroxisome proliferator-activated receptor gamma Rattus norvegicus 99-109 11829461-1 2002 Here we investigated the effect of pioglitazone, a peroxisome proliferator-activated receptor (PPAR)-gamma ligand, on early-phase hepatic fibrogenesis in vivo caused by acute carbon tetrachloride (CCl(4)) administration in the rat. Pioglitazone 35-47 peroxisome proliferator-activated receptor gamma Rattus norvegicus 51-106 12688526-0 2002 A specific peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligand, pioglitazone, ameliorates gastric mucosal damage induced by ischemia and reperfusion in rats. Pioglitazone 81-93 peroxisome proliferator-activated receptor gamma Rattus norvegicus 11-59 12688526-0 2002 A specific peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligand, pioglitazone, ameliorates gastric mucosal damage induced by ischemia and reperfusion in rats. Pioglitazone 81-93 peroxisome proliferator-activated receptor gamma Rattus norvegicus 61-71 12688513-3 2002 The aim of the present study was to determine whether pioglitazone, a specific PPAR-gamma ligand, can ameliorate reperfusion-induced intestinal injury in rats, and whether the agent can inhibit the increase in neutrophil accumulation associated with TNF-alpha expression. Pioglitazone 54-66 peroxisome proliferator-activated receptor gamma Rattus norvegicus 79-89 11319222-7 2001 The thiazolidinedione (TZD) insulin-sensitizing drugs and peroxisome proliferator-activated receptor gamma (PPARgamma) ligands, troglitazone, rosiglitazone, and pioglitazone, strongly and specifically inhibited only ACS4, with an IC(50) of less than 1.5 microm. Pioglitazone 161-173 peroxisome proliferator-activated receptor gamma Rattus norvegicus 58-106 11468209-4 2001 METHODS AND RESULTS: Pioglitazone (0.1 to 10 micromol/L) significantly enhanced cytokine-induced expression of iNOS and NO production in a dose-dependent manner in rat VSMCs, but 15-deoxy-Delta(12,14)-prostaglandin J2 (up to 10 micromol/L), a native peroxisome proliferator-activated receptor-gamma ligand, showed no effect. Pioglitazone 21-33 peroxisome proliferator-activated receptor gamma Rattus norvegicus 250-298 11380325-0 2001 Pioglitazone, a specific PPAR-gamma ligand, inhibits aspirin-induced gastric mucosal injury in rats. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 25-35 11380325-3 2001 The aim of the present study was to determine whether pioglitazone, a specific PPAR-gamma ligand, can ameliorate aspirin-induced gastric mucosal injury in rats, and whether the agent can inhibit the increase in neutrophil accumulation associated with TNF-alpha expression. Pioglitazone 54-66 peroxisome proliferator-activated receptor gamma Rattus norvegicus 79-89 11289109-6 2001 In the third experiment, dietary administration (0.01% in diet for 6 weeks) of pioglitazone (PPARgamma ligand), troglitazone, and bezafibrate effectively suppressed DSS/AOM-induced ACF. Pioglitazone 79-91 peroxisome proliferator-activated receptor gamma Rattus norvegicus 93-102 11411343-8 2001 Pioglitazone is a potent agonist for the peroxisome proliferator-activated receptor, (PPAR)-gamma, that is related to differentiation of adipocytes, and the relationship between TNF-alpha production and PPAR-gamma has been reported. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 41-97 11411343-8 2001 Pioglitazone is a potent agonist for the peroxisome proliferator-activated receptor, (PPAR)-gamma, that is related to differentiation of adipocytes, and the relationship between TNF-alpha production and PPAR-gamma has been reported. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 203-213 11411343-9 2001 Therefore, the agonistic activity of pioglitazone on PPAR-gamma may be involved in the mechanism of reduction of insulin resistance. Pioglitazone 37-49 peroxisome proliferator-activated receptor gamma Rattus norvegicus 53-63 11124825-3 2001 An RXR-specific agonist, Ro47-5944, and a PPAR gamma-specific agonist, AD4833 (pioglitazone hydrochloride), each inhibited LPS-induced NO and TNF-alpha production. Pioglitazone 71-77 peroxisome proliferator-activated receptor gamma Rattus norvegicus 42-52 11272155-10 2001 We conclude that even though WY14643 and pioglitazone, representing PPAR-alpha and PPAR-gamma activation, respectively, may alter muscle lipid supply by different mechanisms, both significantly improve muscle insulin action in the high fat-fed rat model of insulin resistance, and this effect is proportional to the degree to which they reduce muscle lipid accumulation. Pioglitazone 41-53 peroxisome proliferator-activated receptor gamma Rattus norvegicus 83-93 22666229-2 2012 Pioglitazone (PIO), a PPAR-gamma agonist, decreased cell proliferation, interstitial fibrosis, and inflammation, and ameliorated PKD progression in PCK rats (Am. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 22-32 10382590-7 1999 The suppression of PPARgamma mRNA expression caused by 10 nmol/l of TNF-alpha was reversed 60% and 55% by treatment with 10(-4) mol/l of troglitazone and 10(-4) mol/l of pioglitazone, respectively. Pioglitazone 170-182 peroxisome proliferator-activated receptor gamma Rattus norvegicus 19-28 22550475-2 2012 We sought to investigate whether the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligand pioglitazone can attenuate vascular fibrosis in spontaneously hypertensive rats (SHRs) and explore the possible molecular mechanisms. Pioglitazone 106-118 peroxisome proliferator-activated receptor gamma Rattus norvegicus 37-85 22550475-2 2012 We sought to investigate whether the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligand pioglitazone can attenuate vascular fibrosis in spontaneously hypertensive rats (SHRs) and explore the possible molecular mechanisms. Pioglitazone 106-118 peroxisome proliferator-activated receptor gamma Rattus norvegicus 87-97 22550475-11 2012 Pioglitazone treatment significantly increased PPAR-gamma expression and inhibited CTGF expression but had no effect on TGF-beta expression. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 47-57 34233552-6 2021 OBJECTIVE: To investigate the potential effect of PPAR-gamma agonists (pioglitazone, as one member of thiazolidinediones (TZD)) on motor dysfunction in reserpine-induced FM in a rat model. Pioglitazone 71-83 peroxisome proliferator-activated receptor gamma Rattus norvegicus 50-60 34968469-4 2022 MATERIALS AND METHODS: Rats (6 groups) received the vehicle or a combination of CsA (30 mg/kg) with the vehicle, geraniol (50, 100, or 200 mg/kg), or the PPARgamma agonist pioglitazone for 4 weeks. Pioglitazone 172-184 peroxisome proliferator-activated receptor gamma Rattus norvegicus 154-163 19261909-0 2009 A rapid, PPAR-gamma-dependent effect of pioglitazone on the phosphorylation of MYPT. Pioglitazone 40-52 peroxisome proliferator-activated receptor gamma Rattus norvegicus 9-19 34973951-2 2022 Irbesartan and pioglitazone activate Peroxisome proliferator-activated gamma receptor (PPAR-gamma) as partial and full agonists. Pioglitazone 15-27 peroxisome proliferator-activated receptor gamma Rattus norvegicus 37-85 34973951-2 2022 Irbesartan and pioglitazone activate Peroxisome proliferator-activated gamma receptor (PPAR-gamma) as partial and full agonists. Pioglitazone 15-27 peroxisome proliferator-activated receptor gamma Rattus norvegicus 87-97 34468908-3 2022 The current study aimed to investigate the possible beneficial effects of coadministration of VITD with pioglitazone (PIO), a PPAR-gamma agonist, in fructose/streptozotocin (F/STZ) T2DM model in male Wistar rats. Pioglitazone 104-116 peroxisome proliferator-activated receptor gamma Rattus norvegicus 126-136 34468908-3 2022 The current study aimed to investigate the possible beneficial effects of coadministration of VITD with pioglitazone (PIO), a PPAR-gamma agonist, in fructose/streptozotocin (F/STZ) T2DM model in male Wistar rats. Pioglitazone 118-121 peroxisome proliferator-activated receptor gamma Rattus norvegicus 126-136 34233552-10 2021 RESULTS: Pioglitazone significantly relieved fatigue, improved muscle performance, reduced inflammatory cytokines and enhanced antioxidant"s activity, while GW9662, a known PPAR-gamma antagonist, aggravated the FM manifestations in the rat model. Pioglitazone 9-21 peroxisome proliferator-activated receptor gamma Rattus norvegicus 173-183 34681744-1 2021 BACKGROUND: We aimed to examine the anti-calcification and anti-inflammatory effects of pioglitazone as a PPAR-gamma agonist on bioprosthetic-valve-bearing aortic grafts in a rat model of diabetes mellitus (DM). Pioglitazone 88-100 peroxisome proliferator-activated receptor gamma Rattus norvegicus 106-116 34448677-3 2021 The rats were treated with stevioside treatment, PPAR-gamma antagonist GW9662, PPAR-gamma activator pioglitazone or PI3K/AKT inhibitor LY294002 before neurological deficits were assessed using modified Neurological Severity Scale (mNSS) scores. Pioglitazone 100-112 peroxisome proliferator-activated receptor gamma Rattus norvegicus 79-89 34831270-2 2021 Systemic activation of peroxisome proliferator-activated receptor gamma (PPARgamma) with pioglitazone can suppress inflammation-related splanchnic and pulmonary dysfunction in cirrhosis. Pioglitazone 89-101 peroxisome proliferator-activated receptor gamma Rattus norvegicus 23-71 34831270-2 2021 Systemic activation of peroxisome proliferator-activated receptor gamma (PPARgamma) with pioglitazone can suppress inflammation-related splanchnic and pulmonary dysfunction in cirrhosis. Pioglitazone 89-101 peroxisome proliferator-activated receptor gamma Rattus norvegicus 73-82 34831270-12 2021 Activation of systemic, renal vessel and renal tissue levels of PPARgamma by chronic pioglitazone treatment has beneficial effects on the endotoxemia-related TNFalpha/NFkappaB-mediated acute and chronic renal inflammation in cirrhosis. Pioglitazone 85-97 peroxisome proliferator-activated receptor gamma Rattus norvegicus 64-73 34592314-8 2021 PPARgamma agonist pioglitazone treatment in 90% Px rats partially restored glucose homeostasis and beta-cell mass and enhanced expression of SetD7 and Pdx1. Pioglitazone 18-30 peroxisome proliferator-activated receptor gamma Rattus norvegicus 0-9 34654784-3 2021 Pioglitazone, a PPAR-gamma agonist, was shown to decrease the degeneration of native aortic valves. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 16-26 34691163-8 2021 The combined treatment of exogenously administered adiponectin with full PPAR-gamma agonist augmented the improvement in lipid contents and adiponectin concentration and restored arterial stiffness with antioxidant potential effects, indicating the degree of synergism between adiponectin and full PPAR-gamma agonists (pioglitazone). Pioglitazone 319-331 peroxisome proliferator-activated receptor gamma Rattus norvegicus 73-83 34691163-8 2021 The combined treatment of exogenously administered adiponectin with full PPAR-gamma agonist augmented the improvement in lipid contents and adiponectin concentration and restored arterial stiffness with antioxidant potential effects, indicating the degree of synergism between adiponectin and full PPAR-gamma agonists (pioglitazone). Pioglitazone 319-331 peroxisome proliferator-activated receptor gamma Rattus norvegicus 298-308 35553009-4 2022 The PPARgamma effect of TEL was affirmed by using the PPARgamma agonist pioglitazone (PIO), and the antagonist GW9662. Pioglitazone 72-84 peroxisome proliferator-activated receptor gamma Rattus norvegicus 4-13 34593018-2 2021 In the present study, we aimed to investigate the effects of saroglitazar, a dual PPARalpha/gamma agonist, fenofibrate, a PPAR-alpha agonist, and pioglitazone, a PPAR-gamma agonist on an animal model of NASH. Pioglitazone 146-158 peroxisome proliferator-activated receptor gamma Rattus norvegicus 162-172 34111396-8 2021 Co-treatment of adiponectin with pioglitazone significantly amplified the improvement in plasma triglycerides, adiponectin concentration, pulse wave velocity and antioxidant enzymatic activities indicating synergistic effects of adiponectin and full PPAR-gamma agonist. Pioglitazone 33-45 peroxisome proliferator-activated receptor gamma Rattus norvegicus 250-260 34208374-1 2021 Previous studies have demonstrated that pioglitazone, a peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, inhibits ischemia-induced brain injury. Pioglitazone 40-52 peroxisome proliferator-activated receptor gamma Rattus norvegicus 56-104 34208374-1 2021 Previous studies have demonstrated that pioglitazone, a peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, inhibits ischemia-induced brain injury. Pioglitazone 40-52 peroxisome proliferator-activated receptor gamma Rattus norvegicus 106-115 35553009-4 2022 The PPARgamma effect of TEL was affirmed by using the PPARgamma agonist pioglitazone (PIO), and the antagonist GW9662. Pioglitazone 72-84 peroxisome proliferator-activated receptor gamma Rattus norvegicus 54-63 35553009-4 2022 The PPARgamma effect of TEL was affirmed by using the PPARgamma agonist pioglitazone (PIO), and the antagonist GW9662. Pioglitazone 86-89 peroxisome proliferator-activated receptor gamma Rattus norvegicus 4-13 35553009-4 2022 The PPARgamma effect of TEL was affirmed by using the PPARgamma agonist pioglitazone (PIO), and the antagonist GW9662. Pioglitazone 86-89 peroxisome proliferator-activated receptor gamma Rattus norvegicus 54-63 35189097-4 2022 This study aimed to evaluate the effects of pioglitazone, a PPARgamma agonist, on the macrophage phenotype and fibrosis following vocal fold injury in rats. Pioglitazone 44-56 peroxisome proliferator-activated receptor gamma Rattus norvegicus 60-69 35189097-9 2022 On day 56 after injury, pioglitazone inhibited fibrosis, tissue contracture, and hyaluronic acid loss in a PPARgamma-dependent manner. Pioglitazone 24-36 peroxisome proliferator-activated receptor gamma Rattus norvegicus 107-116 35517804-6 2022 Primary rat hippocampal neurons were treated with heme (50 muM) and erastin (50 muM) to induce ferroptosis, followed by the PPARgamma agonist pioglitazone (PDZ, 10 muM) to verify the inhibitory effect of PPARgamma activation on ferroptosis. Pioglitazone 142-154 peroxisome proliferator-activated receptor gamma Rattus norvegicus 124-133 35204074-0 2022 Prophylactic and Ameliorative Effects of PPAR-gamma Agonist Pioglitazone in Improving Oxidative Stress, Germ Cell Apoptosis and Inflammation in Gentamycin-Induced Testicular Damage in Adult Male Albino Rats. Pioglitazone 60-72 peroxisome proliferator-activated receptor gamma Rattus norvegicus 41-51 35051861-13 2022 Isometric force measurements showed that activating PPARgamma by pioglitazone (10 mg/kg/d, intragastric administration) improved the impairment of coronary artery vasodilation, and western blot analysis showed that activating PPARgamma increased the Kv 1.2 and Kv 1.5 protein expression, while inhibiting PPARgamma by GW9662 (10 mg/kg/d, intraperitoneal injection) attenuated these effects in ZDF rats. Pioglitazone 65-77 peroxisome proliferator-activated receptor gamma Rattus norvegicus 52-61 35051861-13 2022 Isometric force measurements showed that activating PPARgamma by pioglitazone (10 mg/kg/d, intragastric administration) improved the impairment of coronary artery vasodilation, and western blot analysis showed that activating PPARgamma increased the Kv 1.2 and Kv 1.5 protein expression, while inhibiting PPARgamma by GW9662 (10 mg/kg/d, intraperitoneal injection) attenuated these effects in ZDF rats. Pioglitazone 65-77 peroxisome proliferator-activated receptor gamma Rattus norvegicus 226-235 35051861-13 2022 Isometric force measurements showed that activating PPARgamma by pioglitazone (10 mg/kg/d, intragastric administration) improved the impairment of coronary artery vasodilation, and western blot analysis showed that activating PPARgamma increased the Kv 1.2 and Kv 1.5 protein expression, while inhibiting PPARgamma by GW9662 (10 mg/kg/d, intraperitoneal injection) attenuated these effects in ZDF rats. Pioglitazone 65-77 peroxisome proliferator-activated receptor gamma Rattus norvegicus 305-314 35204074-2 2022 Pioglitazone (PIO) is one of the PPAR-gamma agonists, having anti-oxidant and anti-inflammatory effects. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 33-43 35204074-2 2022 Pioglitazone (PIO) is one of the PPAR-gamma agonists, having anti-oxidant and anti-inflammatory effects. Pioglitazone 14-17 peroxisome proliferator-activated receptor gamma Rattus norvegicus 33-43 33894214-0 2021 Dose-dependent effects of prenatal exposure of pioglitazone, the PPARgamma agonist, on the hippocampus development and learning and memory performance of rat offspring. Pioglitazone 47-59 peroxisome proliferator-activated receptor gamma Rattus norvegicus 65-74 35042967-0 2022 Retraction Note: Carvacrol and PPARgamma agonist, pioglitazone, affects inhaled paraquat-induced lung injury in rats. Pioglitazone 50-62 peroxisome proliferator-activated receptor gamma Rattus norvegicus 31-40 33894214-1 2021 It is known that pioglitazone, defined as a PPARgamma agonist, has neuron-protective properties in nervous system disorders. Pioglitazone 17-29 peroxisome proliferator-activated receptor gamma Rattus norvegicus 44-53 33864097-10 2021 Pioglitazone acting on PPARgamma activates PI3K/Akt pathway in ischemic brain tissue. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 23-32 33836209-8 2021 Further application of PPAR-gamma agonist (pioglitazone) and antagonist (GW9662) in H9C2 cells revealed that the up-regulation of PPAR-gamma expression induced by T-2 toxin is a self-preservation phenomenon, and increasing exogenous PPAR-gamma can alleviate the increase in TGF-beta1 caused by T-2 toxin, thereby playing a role in relieving cardiac fibrosis. Pioglitazone 43-55 peroxisome proliferator-activated receptor gamma Rattus norvegicus 130-140 33836209-8 2021 Further application of PPAR-gamma agonist (pioglitazone) and antagonist (GW9662) in H9C2 cells revealed that the up-regulation of PPAR-gamma expression induced by T-2 toxin is a self-preservation phenomenon, and increasing exogenous PPAR-gamma can alleviate the increase in TGF-beta1 caused by T-2 toxin, thereby playing a role in relieving cardiac fibrosis. Pioglitazone 43-55 peroxisome proliferator-activated receptor gamma Rattus norvegicus 130-140 33864097-1 2021 The present study elucidates the neuroprotective mechanisms of the PPARgamma (peroxisome proliferator-activated receptor gamma) agonist pioglitazone in survival of ischemic neurons following middle cerebral artery occlusion with reperfusion (MCAO). Pioglitazone 136-148 peroxisome proliferator-activated receptor gamma Rattus norvegicus 67-76 33864097-1 2021 The present study elucidates the neuroprotective mechanisms of the PPARgamma (peroxisome proliferator-activated receptor gamma) agonist pioglitazone in survival of ischemic neurons following middle cerebral artery occlusion with reperfusion (MCAO). Pioglitazone 136-148 peroxisome proliferator-activated receptor gamma Rattus norvegicus 78-126 33864097-3 2021 In primary cortical neurons, pioglitazone suppressed the glutamate-induced release of lactate dehydrogenase by a PPARgamma-dependent mechanism. Pioglitazone 29-41 peroxisome proliferator-activated receptor gamma Rattus norvegicus 113-122 33854134-0 2021 Carvacrol and PPARgamma agonist, pioglitazone, affects inhaled paraquat-induced lung injury in rats. Pioglitazone 33-45 peroxisome proliferator-activated receptor gamma Rattus norvegicus 14-23 33854134-6 2021 The synergic effect of carvacrol and pioglitazone suggests PPAR-gamma receptor mediated effects of carvacrol on inhaled PQ-induced lung injury. Pioglitazone 37-49 peroxisome proliferator-activated receptor gamma Rattus norvegicus 59-69 32984914-2 2021 This study aimed to investigate the potential protective effects of pioglitazone (Pio) and curcumin (Cur) against DCM in type 1 diabetes mellitus (T1DM), with pointing to their role on Ca+2/calmodulin-dependent protein kinase II (CaMKII) and peroxisome proliferator-activated receptor gamma (PPAR-gamma) expression. Pioglitazone 68-80 peroxisome proliferator-activated receptor gamma Rattus norvegicus 242-290 33623853-1 2021 Pioglitazone is a Food and Drug Administration-approved thiazolidinedione (TZD) derivative and peroxisome proliferator-activated receptor gamma (PPARgamma) agonist and used for the treatment of diabetes mellitus (DM). Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 95-143 33623853-1 2021 Pioglitazone is a Food and Drug Administration-approved thiazolidinedione (TZD) derivative and peroxisome proliferator-activated receptor gamma (PPARgamma) agonist and used for the treatment of diabetes mellitus (DM). Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 145-154 32984914-2 2021 This study aimed to investigate the potential protective effects of pioglitazone (Pio) and curcumin (Cur) against DCM in type 1 diabetes mellitus (T1DM), with pointing to their role on Ca+2/calmodulin-dependent protein kinase II (CaMKII) and peroxisome proliferator-activated receptor gamma (PPAR-gamma) expression. Pioglitazone 68-80 peroxisome proliferator-activated receptor gamma Rattus norvegicus 292-302 32942156-16 2020 15 min prior to pioglitazone) reversed the effects of pioglitazone on BCP and regulations of PPARgamma/PTEN/mTOR signal. Pioglitazone 16-28 peroxisome proliferator-activated receptor gamma Rattus norvegicus 93-102 32610339-1 2021 Peroxisome proliferator-activated receptor gamma (PPARgamma) is an intracellular transcription factor whose signaling activation by the selective agonist pioglitazone reduces alcohol drinking and alcohol-seeking behavior in rats. Pioglitazone 154-166 peroxisome proliferator-activated receptor gamma Rattus norvegicus 0-48 32610339-1 2021 Peroxisome proliferator-activated receptor gamma (PPARgamma) is an intracellular transcription factor whose signaling activation by the selective agonist pioglitazone reduces alcohol drinking and alcohol-seeking behavior in rats. Pioglitazone 154-166 peroxisome proliferator-activated receptor gamma Rattus norvegicus 50-59 33170841-1 2020 Pioglitazone, a therapeutic drug for diabetes, possesses full PPAR-gamma agonist activity and increase circulating adiponectin plasma concentration. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 62-72 32942156-0 2020 The analgesic effects of pioglitazone in the bone cancer pain rats via regulating the PPARgamma/PTEN/mTOR signaling pathway in the spinal dorsal horn. Pioglitazone 25-37 peroxisome proliferator-activated receptor gamma Rattus norvegicus 86-95 32942156-16 2020 15 min prior to pioglitazone) reversed the effects of pioglitazone on BCP and regulations of PPARgamma/PTEN/mTOR signal. Pioglitazone 54-66 peroxisome proliferator-activated receptor gamma Rattus norvegicus 93-102 32942156-17 2020 CONCLUSIONS: Intrathecal pioglitazone administration alleviates BCP by regulating the PPARgamma/PTEN/mTOR signal in the SDH. Pioglitazone 25-37 peroxisome proliferator-activated receptor gamma Rattus norvegicus 86-95 32676772-3 2020 Recent studies support a role of PPARs in alcoholism and pioglitazone: a PPARgamma agonist used for treatment of type 2 diabetes showed efficacy in reducing alcohol drinking, stress-induced relapse, and alcohol withdrawal syndrome in rats. Pioglitazone 57-69 peroxisome proliferator-activated receptor gamma Rattus norvegicus 73-82 32676772-6 2020 Pre-treatment with the selective PPARgamma antagonist GW9662 (5 mg/kg) completely prevented the effect of pioglitazone, demonstrating that its action is specifically mediated by activation of PPARgamma. Pioglitazone 106-118 peroxisome proliferator-activated receptor gamma Rattus norvegicus 33-42 32676772-6 2020 Pre-treatment with the selective PPARgamma antagonist GW9662 (5 mg/kg) completely prevented the effect of pioglitazone, demonstrating that its action is specifically mediated by activation of PPARgamma. Pioglitazone 106-118 peroxisome proliferator-activated receptor gamma Rattus norvegicus 192-201 32579381-4 2020 Since peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonists accelerate lung maturation by stimulating alveolar epithelial-mesenchymal interactions, independent of fetal sex, we hypothesized that the effect of PPAR-gamma agonist pioglitazone (PGZ) would be sex-independent. Pioglitazone 259-262 peroxisome proliferator-activated receptor gamma Rattus norvegicus 56-66 32579381-0 2020 Antenatal PPAR-gamma agonist pioglitazone stimulates fetal lung maturation equally in males and females. Pioglitazone 29-41 peroxisome proliferator-activated receptor gamma Rattus norvegicus 10-20 32579381-4 2020 Since peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonists accelerate lung maturation by stimulating alveolar epithelial-mesenchymal interactions, independent of fetal sex, we hypothesized that the effect of PPAR-gamma agonist pioglitazone (PGZ) would be sex-independent. Pioglitazone 245-257 peroxisome proliferator-activated receptor gamma Rattus norvegicus 6-54 32579381-4 2020 Since peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonists accelerate lung maturation by stimulating alveolar epithelial-mesenchymal interactions, independent of fetal sex, we hypothesized that the effect of PPAR-gamma agonist pioglitazone (PGZ) would be sex-independent. Pioglitazone 245-257 peroxisome proliferator-activated receptor gamma Rattus norvegicus 56-66 31215278-1 2019 Aim: The effect of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist pioglitazone on the brain tissues oxidative damage and learning and memory impairment in the juvenile hypothyroid rats was evaluated. Pioglitazone 89-101 peroxisome proliferator-activated receptor gamma Rattus norvegicus 69-79 32832706-2 2020 We prepared a surface modified poly (D, L-lactide-co-glycolide) i.e. PLGA nanoparticles for delivery of pioglitazone-a peroxisome proliferator-activated receptor-gamma agonist to posterior segment of the eye by topical administration. Pioglitazone 104-116 peroxisome proliferator-activated receptor gamma Rattus norvegicus 119-167 32243355-2 2020 Pioglitazone, a PPARgamma ligand of the thiazolidinedione class, exerts several pleiotropic effects including neuroprotection in addition to reducing blood glucose and insulin resistance; however, its mechanism remains obscure. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 16-25 31506251-3 2019 Previous studies have demonstrated that pioglitazone (PIO), a PPAR-gamma agonists, can ameliorate renal fibrosis and protect renal function. Pioglitazone 40-52 peroxisome proliferator-activated receptor gamma Rattus norvegicus 62-72 31506251-3 2019 Previous studies have demonstrated that pioglitazone (PIO), a PPAR-gamma agonists, can ameliorate renal fibrosis and protect renal function. Pioglitazone 54-57 peroxisome proliferator-activated receptor gamma Rattus norvegicus 62-72 32893590-10 2020 As compared with high glucose group, Sal B and the pioglitazone(PIO) can greatly enhance the expression of PPARgamma, PTEN at mRNA and protein levels, enhance the expression of E-cadherin at protein levels, and reduce the expression of alpha-SMA, p-Akt~((Thr308))protein level(P<0.05), there was no significant difference between the two groups. Pioglitazone 51-63 peroxisome proliferator-activated receptor gamma Rattus norvegicus 107-116 32353564-5 2020 AutoDock Vina used for potential PPAR alpha/gamma dual agonists and 6 compounds 9a, 9g, 9 m, 9n, 9o, and 9r were identified comparable to PPAR gamma agonist Pioglitazone on the basis of their affinity scores and further their in-silico toxicity and in-silico ADME properties. Pioglitazone 157-169 peroxisome proliferator-activated receptor gamma Rattus norvegicus 138-148 32015419-3 2020 The peroxisome proliferator-activator receptor gamma (PPARgamma) agonist pioglitazone slows disease progression in the PCK rat model for PKD. Pioglitazone 73-85 peroxisome proliferator-activated receptor gamma Rattus norvegicus 4-52 32015419-3 2020 The peroxisome proliferator-activator receptor gamma (PPARgamma) agonist pioglitazone slows disease progression in the PCK rat model for PKD. Pioglitazone 73-85 peroxisome proliferator-activated receptor gamma Rattus norvegicus 54-63 32190383-0 2020 The Peroxisome Proliferator-Activated Receptor gamma Agonist Pioglitazone Protects Vascular Endothelial Function in Hypercholesterolemic Rats by Inhibiting Myeloperoxidase. Pioglitazone 61-73 peroxisome proliferator-activated receptor gamma Rattus norvegicus 4-52 32190383-2 2020 The present study was designed to determine whether myeloperoxidase (MPO) mediates HC-induced endothelial dysfunction and the role of the PPARgamma agonist pioglitazone (PIO) in attenuating endothelial dysfunction. Pioglitazone 156-168 peroxisome proliferator-activated receptor gamma Rattus norvegicus 138-147 31730865-7 2019 Activation of PPAR-gamma by pioglitazone reduced BP, restored the blunted NO levels, increased endothelial NO synthase (eNOS) expression, and restored the antioxidant status of L-NAME-induced hypertensive rats. Pioglitazone 28-40 peroxisome proliferator-activated receptor gamma Rattus norvegicus 14-24 31730865-8 2019 Moreover, the antihypertensive activity of pioglitazone was associated with a reduction in ER stress and this effect was PPAR-gamma dependent. Pioglitazone 43-55 peroxisome proliferator-activated receptor gamma Rattus norvegicus 121-131 31712626-5 2019 In SHR, the PPARgamma agonist pioglitazone (2.5 mg/Kg day, 28 days) reduced the increased ETA levels and increased those of ETB. Pioglitazone 30-42 peroxisome proliferator-activated receptor gamma Rattus norvegicus 12-21 31314915-7 2019 Meanwhile, intrathecal injection of the Cdk5 inhibitor roscovitine, the mitogen-activated ERK kinase (MEK) inhibitor U0126 and the PPARgamma agonist pioglitazone prevented or reversed behavioural allodynia, increased pPPARgamma expression, inhibited astrocyte activation and alleviated proinflammatory cytokine (tumour necrosis factor-alpha, IL-1beta, and IL-6) release from activated astrocytes. Pioglitazone 149-161 peroxisome proliferator-activated receptor gamma Rattus norvegicus 131-140 31215278-12 2019 Significance: Our finding in the present study indicated that PPARgamma agonist pioglitazone prevented the brain tissues from oxidative damage and learning and memory impairments in juvenile hypothyroid rats. Pioglitazone 80-92 peroxisome proliferator-activated receptor gamma Rattus norvegicus 62-71 32274400-1 2019 Background: Neuroprotective mechanisms triggered by peroxisome proliferator-activated receptor-gamma agonist: pioglitazone (PIO) and glucagon-like peptide 1 analog: exendin-4 (Ex-4) in neurological diseases were reported, but whether mitochondrial biogenesis is involved or not in their neuro-protective mechanisms in type 1 Diabetes Mellitus (T1DM); has not been studied before. Pioglitazone 110-122 peroxisome proliferator-activated receptor gamma Rattus norvegicus 52-100 32274400-1 2019 Background: Neuroprotective mechanisms triggered by peroxisome proliferator-activated receptor-gamma agonist: pioglitazone (PIO) and glucagon-like peptide 1 analog: exendin-4 (Ex-4) in neurological diseases were reported, but whether mitochondrial biogenesis is involved or not in their neuro-protective mechanisms in type 1 Diabetes Mellitus (T1DM); has not been studied before. Pioglitazone 124-127 peroxisome proliferator-activated receptor gamma Rattus norvegicus 52-100 31277946-5 2019 Activation of PPARgamma by pioglitazone suppressed S1P-induced activation of calcineurin/NFATc3 signaling pathway and followed OPN up-regulation. Pioglitazone 27-39 peroxisome proliferator-activated receptor gamma Rattus norvegicus 14-23 31184312-0 2019 Age-dependent effect of PPARgamma agonist pioglitazone on kidney signaling in borderline hypertensive rats. Pioglitazone 42-54 peroxisome proliferator-activated receptor gamma Rattus norvegicus 24-33 31132685-0 2019 PPAR-gamma agonist pioglitazone reduces microglial proliferation and NF-kappaB activation in the substantia nigra in the 6-hydroxydopamine model of Parkinson"s disease. Pioglitazone 19-31 peroxisome proliferator-activated receptor gamma Rattus norvegicus 0-10 31132685-3 2019 METHODS: The effects of a 5-day administration of the PPAR-gamma agonist pioglitazone (30 mg/kg) in male Wistar rats that received bilateral intranigral infusions of 6-OHDA. Pioglitazone 73-85 peroxisome proliferator-activated receptor gamma Rattus norvegicus 54-64 31128204-0 2019 Beneficial effects of pioglitazone, a selective peroxisome proliferator-activated receptor-gamma agonist in prenatal valproic acid-induced behavioral and biochemical autistic like features in Wistar rats. Pioglitazone 22-34 peroxisome proliferator-activated receptor gamma Rattus norvegicus 48-96 31379559-0 2019 Pioglitazone Reduces beta Amyloid Levels via Inhibition of PPARgamma Phosphorylation in a Neuronal Model of Alzheimer"s Disease. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 59-68 31379559-7 2019 The present study confirmed this hypothesis by showing that PPARgamma agonist pioglitazone attenuated the neuronal apoptosis of primary rat hippocampal neurons induced by Abeta1-42, downregulated CDK5 expression, weakened the binding of CDK5 to PPARgamma, reduced PPARgamma phosphorylation, increased the expression of PPARgamma and IDE, decreased the expression of BACE1, reduced APP production, and downregulated intraneuronal Abeta1-42 levels. Pioglitazone 78-90 peroxisome proliferator-activated receptor gamma Rattus norvegicus 60-69 31379559-7 2019 The present study confirmed this hypothesis by showing that PPARgamma agonist pioglitazone attenuated the neuronal apoptosis of primary rat hippocampal neurons induced by Abeta1-42, downregulated CDK5 expression, weakened the binding of CDK5 to PPARgamma, reduced PPARgamma phosphorylation, increased the expression of PPARgamma and IDE, decreased the expression of BACE1, reduced APP production, and downregulated intraneuronal Abeta1-42 levels. Pioglitazone 78-90 peroxisome proliferator-activated receptor gamma Rattus norvegicus 245-254 31379559-7 2019 The present study confirmed this hypothesis by showing that PPARgamma agonist pioglitazone attenuated the neuronal apoptosis of primary rat hippocampal neurons induced by Abeta1-42, downregulated CDK5 expression, weakened the binding of CDK5 to PPARgamma, reduced PPARgamma phosphorylation, increased the expression of PPARgamma and IDE, decreased the expression of BACE1, reduced APP production, and downregulated intraneuronal Abeta1-42 levels. Pioglitazone 78-90 peroxisome proliferator-activated receptor gamma Rattus norvegicus 245-254 31379559-7 2019 The present study confirmed this hypothesis by showing that PPARgamma agonist pioglitazone attenuated the neuronal apoptosis of primary rat hippocampal neurons induced by Abeta1-42, downregulated CDK5 expression, weakened the binding of CDK5 to PPARgamma, reduced PPARgamma phosphorylation, increased the expression of PPARgamma and IDE, decreased the expression of BACE1, reduced APP production, and downregulated intraneuronal Abeta1-42 levels. Pioglitazone 78-90 peroxisome proliferator-activated receptor gamma Rattus norvegicus 245-254 31379559-10 2019 In conclusion, this study demonstrated that pioglitazone could inhibit the phosphorylation of PPARgamma in vitro by inhibiting CDK5 expression, which in turn affected the expression of PPARgamma target genes Ide and Bace1, thereby promoting Abeta degradation and reducing Abeta production. Pioglitazone 44-56 peroxisome proliferator-activated receptor gamma Rattus norvegicus 94-103 31379559-10 2019 In conclusion, this study demonstrated that pioglitazone could inhibit the phosphorylation of PPARgamma in vitro by inhibiting CDK5 expression, which in turn affected the expression of PPARgamma target genes Ide and Bace1, thereby promoting Abeta degradation and reducing Abeta production. Pioglitazone 44-56 peroxisome proliferator-activated receptor gamma Rattus norvegicus 185-194 32215295-9 2020 The obtained results revealed that: 1) increased expression of IL-6, NO and Caspase-3 in serum and cerebrospinal fluid in patients after TBI, and decreased PPARgamma in brain tissue; 2) pioglitazone could improve neurobehavioral and reduce brain edema in rats after TBI; 3) the protective effect of pioglitazone was achieved by activating PPARgamma and reducing NF-kappaB and IL-6. Pioglitazone 186-198 peroxisome proliferator-activated receptor gamma Rattus norvegicus 339-348 32215295-10 2020 The neuroprotective effect of pioglitazone on TBI was mediated through the PPARgamma/NF-kappaB/IL-6 pathway. Pioglitazone 30-42 peroxisome proliferator-activated receptor gamma Rattus norvegicus 75-84 31184312-1 2019 The peroxisome proliferator-activated receptor gamma (PPARgamma) is a nuclear receptor and nutrition factor which takes part in the cellular signaling by several agonists such as pioglitazone. Pioglitazone 179-191 peroxisome proliferator-activated receptor gamma Rattus norvegicus 4-52 31184312-1 2019 The peroxisome proliferator-activated receptor gamma (PPARgamma) is a nuclear receptor and nutrition factor which takes part in the cellular signaling by several agonists such as pioglitazone. Pioglitazone 179-191 peroxisome proliferator-activated receptor gamma Rattus norvegicus 54-63 30896803-0 2019 Pioglitazone prevents sevoflurane-induced neuroinflammation and cognitive decline in a rat model of chronic intermittent hypoxia by upregulating hippocampal PPAR-gamma. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 157-167 30896803-3 2019 In the present study, it was examined whether treatment with PPAR-gamma agonist pioglitazone (PIO) is beneficial in counteracting SEV-induced neuroinflammation and cognitive decline in a rat model of CIH. Pioglitazone 80-92 peroxisome proliferator-activated receptor gamma Rattus norvegicus 61-71 30896803-3 2019 In the present study, it was examined whether treatment with PPAR-gamma agonist pioglitazone (PIO) is beneficial in counteracting SEV-induced neuroinflammation and cognitive decline in a rat model of CIH. Pioglitazone 94-97 peroxisome proliferator-activated receptor gamma Rattus norvegicus 61-71 30902059-5 2019 In the in vitro study, the ADRCs grafts released APN, which was significantly enhanced by the PPARgamma agonist (PGZ, pioglitazone). Pioglitazone 118-130 peroxisome proliferator-activated receptor gamma Rattus norvegicus 94-103 30522964-4 2019 Pioglitazone blocked these visceral changes, and GW9662, a peroxisome proliferator-activated receptor gamma (PPAR-gamma) antagonist fully reversed the effect by pioglitazone. Pioglitazone 161-173 peroxisome proliferator-activated receptor gamma Rattus norvegicus 59-107 30873215-6 2019 (2) The decreased chemerin/CMKLR1 in the EDM rats were reversed by PPARgamma antagonist GW9662 and further strengthened by PPARgamma agonist pioglitazones. Pioglitazone 141-154 peroxisome proliferator-activated receptor gamma Rattus norvegicus 123-132 31156787-1 2019 Objectives: Pioglitazone (PGZ), a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist, has significant neuroprotective effects and has been reported to regulate inflammatory processes. Pioglitazone 12-24 peroxisome proliferator-activated receptor gamma Rattus norvegicus 34-82 31156787-1 2019 Objectives: Pioglitazone (PGZ), a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist, has significant neuroprotective effects and has been reported to regulate inflammatory processes. Pioglitazone 12-24 peroxisome proliferator-activated receptor gamma Rattus norvegicus 84-94 31156787-1 2019 Objectives: Pioglitazone (PGZ), a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist, has significant neuroprotective effects and has been reported to regulate inflammatory processes. Pioglitazone 26-29 peroxisome proliferator-activated receptor gamma Rattus norvegicus 34-82 31156787-1 2019 Objectives: Pioglitazone (PGZ), a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist, has significant neuroprotective effects and has been reported to regulate inflammatory processes. Pioglitazone 26-29 peroxisome proliferator-activated receptor gamma Rattus norvegicus 84-94 30522964-5 2019 These results suggest that PPAR-gamma activation by pioglitazone may be useful for IBS treatment. Pioglitazone 52-64 peroxisome proliferator-activated receptor gamma Rattus norvegicus 27-37 30508725-0 2019 Treatment with the synthetic PPARG ligand pioglitazone ameliorates early ovarian alterations induced by dehydroepiandrosterone in prepubertal rats. Pioglitazone 42-54 peroxisome proliferator-activated receptor gamma Rattus norvegicus 29-34 30508725-4 2019 The aim of the present study was to evaluate whether PPARG activation (using the synthetic ligand pioglitazone (PGZ)) ameliorates the alterations in early ovarian function induced by androgen excess. Pioglitazone 98-110 peroxisome proliferator-activated receptor gamma Rattus norvegicus 53-58 30508725-4 2019 The aim of the present study was to evaluate whether PPARG activation (using the synthetic ligand pioglitazone (PGZ)) ameliorates the alterations in early ovarian function induced by androgen excess. Pioglitazone 112-115 peroxisome proliferator-activated receptor gamma Rattus norvegicus 53-58 30508725-7 2019 RESULTS: PGZ prevented the inactivation of ovarian PPARG induced by androgen excess by increasing PPARG itself and the gene expression of PPARG-coactivator 1 alpha (PGC1A), and by decreasing the gene expression of nuclear co-repressor (NCOR). Pioglitazone 9-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 51-56 30508725-7 2019 RESULTS: PGZ prevented the inactivation of ovarian PPARG induced by androgen excess by increasing PPARG itself and the gene expression of PPARG-coactivator 1 alpha (PGC1A), and by decreasing the gene expression of nuclear co-repressor (NCOR). Pioglitazone 9-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 98-103 30522964-4 2019 Pioglitazone blocked these visceral changes, and GW9662, a peroxisome proliferator-activated receptor gamma (PPAR-gamma) antagonist fully reversed the effect by pioglitazone. Pioglitazone 161-173 peroxisome proliferator-activated receptor gamma Rattus norvegicus 109-119 29980143-0 2018 The peroxisome proliferator-activated receptor gamma agonist pioglitazone improves nitric oxide availability, renin-angiotensin system and aberrant redox regulation in the kidney of pre-hypertensive rats. Pioglitazone 61-73 peroxisome proliferator-activated receptor gamma Rattus norvegicus 4-52 30481177-5 2018 A 13-week treatment with the PPARgamma agonist pioglitazone reversed most of these signatures: Pioglitazone improved glycemic control and the fatty acid profile, elevated amino acid levels in the liver, but decreased branched chain amino acids in serum. Pioglitazone 47-59 peroxisome proliferator-activated receptor gamma Rattus norvegicus 29-38 30481177-5 2018 A 13-week treatment with the PPARgamma agonist pioglitazone reversed most of these signatures: Pioglitazone improved glycemic control and the fatty acid profile, elevated amino acid levels in the liver, but decreased branched chain amino acids in serum. Pioglitazone 95-107 peroxisome proliferator-activated receptor gamma Rattus norvegicus 29-38 28716464-4 2018 Omega-3 fatty acids and Peroxisome Proliferator Activated Receptor gamma (PPAR-gamma) agonists as pioglitazone are used for decreasing inflammation. Pioglitazone 98-110 peroxisome proliferator-activated receptor gamma Rattus norvegicus 24-72 28716464-4 2018 Omega-3 fatty acids and Peroxisome Proliferator Activated Receptor gamma (PPAR-gamma) agonists as pioglitazone are used for decreasing inflammation. Pioglitazone 98-110 peroxisome proliferator-activated receptor gamma Rattus norvegicus 74-84 29984341-1 2018 Purpose: To understand the therapeutic potential of pioglitazone, a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist with a propensity to cause bladder mucosal proliferation, on interstitial cystitis (IC) in a rat model. Pioglitazone 52-64 peroxisome proliferator-activated receptor gamma Rattus norvegicus 68-116 29984341-1 2018 Purpose: To understand the therapeutic potential of pioglitazone, a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist with a propensity to cause bladder mucosal proliferation, on interstitial cystitis (IC) in a rat model. Pioglitazone 52-64 peroxisome proliferator-activated receptor gamma Rattus norvegicus 118-128 29984341-9 2018 Conclusions: Pioglitazone, a PPAR-gamma agonist, improved bladder function in cyclophosphamide-induced cystitis by both observed urinary frequency and measured cystometric capacity. Pioglitazone 13-25 peroxisome proliferator-activated receptor gamma Rattus norvegicus 29-39 29695452-4 2018 In the SU5416/hypoxia (SuHx) rat model, oral treatment with the PPARgamma agonist pioglitazone completely reverses severe PAH and vascular remodeling and prevents RV failure. Pioglitazone 82-94 peroxisome proliferator-activated receptor gamma Rattus norvegicus 64-73 29966944-0 2018 Protective effect of pioglitazone on ovarian ischemia reperfusion injury of female rats via modulation of peroxisome proliferator activated receptor gamma and heme-oxygenase 1. Pioglitazone 21-33 peroxisome proliferator-activated receptor gamma Rattus norvegicus 106-154 30127742-2 2018 Our previous studies have shown that pioglitazone, a peroxisome proliferators-activated receptor (PPAR)-gamma agonist used in type 2 diabetes, protects against renal IRI; however, the molecular mechanism underlying the renoprotective effects of pioglitazone is still unclear. Pioglitazone 37-49 peroxisome proliferator-activated receptor gamma Rattus norvegicus 53-109 30127742-9 2018 Moreover, GW9662, as a selective inhibitor of PPAR-gamma, inhibited the protective effects of pioglitazone. Pioglitazone 94-106 peroxisome proliferator-activated receptor gamma Rattus norvegicus 46-56 29959408-1 2018 This study was designed to assess whether the protective effects of bone marrow-derived mesenchymal stem cells (MSCs) against diabetes could be enhanced by pioglitazone (PIO), a PPARgamma agonist. Pioglitazone 156-168 peroxisome proliferator-activated receptor gamma Rattus norvegicus 178-187 29959408-1 2018 This study was designed to assess whether the protective effects of bone marrow-derived mesenchymal stem cells (MSCs) against diabetes could be enhanced by pioglitazone (PIO), a PPARgamma agonist. Pioglitazone 170-173 peroxisome proliferator-activated receptor gamma Rattus norvegicus 178-187 29110250-0 2018 Treatment with the PPARgamma Agonist Pioglitazone in the Early Post-ischemia Phase Inhibits Pro-inflammatory Responses and Promotes Neurogenesis Via the Activation of Innate- and Bone Marrow-Derived Stem Cells in Rats. Pioglitazone 37-49 peroxisome proliferator-activated receptor gamma Rattus norvegicus 19-28 29110250-3 2018 Elsewhere, we demonstrated that treatment with the PPARgamma agonist pioglitazone (PGZ) before cerebral ischemia induction reduced brain damage and activated survival-related genes in ovariectomized (OVX) rats. Pioglitazone 69-81 peroxisome proliferator-activated receptor gamma Rattus norvegicus 51-60 29110250-3 2018 Elsewhere, we demonstrated that treatment with the PPARgamma agonist pioglitazone (PGZ) before cerebral ischemia induction reduced brain damage and activated survival-related genes in ovariectomized (OVX) rats. Pioglitazone 83-86 peroxisome proliferator-activated receptor gamma Rattus norvegicus 51-60 29177991-0 2018 Correction to: Treatment with the PPARgamma Agonist Pioglitazone in the Early Post-ischemia Phase Inhibits Pro-inflammatory Responses and Promotes Neurogenesis Via the Activation of Innate- and Bone Marrow-Derived Stem Cells in Rats. Pioglitazone 52-64 peroxisome proliferator-activated receptor gamma Rattus norvegicus 34-43 29716851-1 2018 Pioglitazone, peroxisome proliferator-activated receptor (PPAR-gamma) agonist, is a therapeutic drug for diabetes. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 58-68 29980143-3 2018 In our study we focused on the effect of PPARgamma agonist pioglitazone on changes in the nitric oxide synthase (NOS) expression and activity, the renin-angiotensin system (RAS) cascade, and redox homeostasis signaling pathways in the renal cortex of young pre hypertensive rat models. Pioglitazone 59-71 peroxisome proliferator-activated receptor gamma Rattus norvegicus 41-50 29162435-2 2018 Pioglitazone, a selective peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist, has been shown to exert antiinflammatory and antidepressant effects and modulate neural plasticity in several neurodegenerative disorders. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 26-74 29162435-2 2018 Pioglitazone, a selective peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist, has been shown to exert antiinflammatory and antidepressant effects and modulate neural plasticity in several neurodegenerative disorders. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 76-86 29212876-5 2018 In addition, activation of PPARgamma by pioglitazone or targeting ERK1/2/Egr-1 suppressed leptin-induced PASMC proliferation. Pioglitazone 40-52 peroxisome proliferator-activated receptor gamma Rattus norvegicus 27-36 29054390-2 2018 Pioglitazone (PIO), a selective peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, has been applied to enhance insulin sensitivity. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 32-80 29054390-2 2018 Pioglitazone (PIO), a selective peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, has been applied to enhance insulin sensitivity. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 82-91 29054390-2 2018 Pioglitazone (PIO), a selective peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, has been applied to enhance insulin sensitivity. Pioglitazone 14-17 peroxisome proliferator-activated receptor gamma Rattus norvegicus 32-80 29054390-2 2018 Pioglitazone (PIO), a selective peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, has been applied to enhance insulin sensitivity. Pioglitazone 14-17 peroxisome proliferator-activated receptor gamma Rattus norvegicus 82-91 30132829-7 2018 Preincubation of rat ASMCs with pioglitazone, a PPAR-gamma activator, blocked TGF-beta1-induced activation of Smad2/3 and its downstream targets changes of miR-21, PTEN, Akt, FOXO1, and cyclin D1, resulting in the inhibition of rat ASMC proliferation. Pioglitazone 32-44 peroxisome proliferator-activated receptor gamma Rattus norvegicus 48-58 29554649-1 2018 BACKGROUND/AIMS: Recent researches highlighted the protective potential of pioglitazone, a PPAR-gamma agonist, in the progression of cerebral ischemia-reperfusion injury. Pioglitazone 75-87 peroxisome proliferator-activated receptor gamma Rattus norvegicus 91-101 29554649-9 2018 However, these protective effects of pioglitazone were neutralized with the use of GW9662, a PPAR-gamma inhibitor. Pioglitazone 37-49 peroxisome proliferator-activated receptor gamma Rattus norvegicus 93-103 29554649-12 2018 CONCLUSION: The neuroprotection of pioglitazone was attributable to the alleviated ischemia/hypoxia-induced pyroptosis and was also associated with the PPARgamma-mediated suppression of HGMB-1/RAGE signaling pathway. Pioglitazone 35-47 peroxisome proliferator-activated receptor gamma Rattus norvegicus 152-161 29428947-0 2018 A Combination of the Aerosolized PPAR-gamma Agonist Pioglitazone and a Synthetic Surfactant Protein B Peptide Mimic Prevents Hyperoxia-Induced Neonatal Lung Injury in Rats. Pioglitazone 52-64 peroxisome proliferator-activated receptor gamma Rattus norvegicus 33-43 29024521-9 2018 The early increased PPARgamma expression by pioglitazone might reduce serum triglycerides and decrease the CUG of the visceral adipose tissue in SGA. Pioglitazone 44-56 peroxisome proliferator-activated receptor gamma Rattus norvegicus 20-29 29428947-4 2018 OBJECTIVES: Since PPAR-gamma agonists have been demonstrated to promote neonatal lung maturation and injury repair, we hypothesized that a formulation of a PPAR-gamma agonist, pioglitazone (PGZ) and a synthetic lung surfactant (a surfactant protein B peptide mimic, B-YL) combined would stimulate lung maturation and block hyperoxia-induced neonatal lung injury more effectively than either modality alone. Pioglitazone 176-188 peroxisome proliferator-activated receptor gamma Rattus norvegicus 18-28 29428947-4 2018 OBJECTIVES: Since PPAR-gamma agonists have been demonstrated to promote neonatal lung maturation and injury repair, we hypothesized that a formulation of a PPAR-gamma agonist, pioglitazone (PGZ) and a synthetic lung surfactant (a surfactant protein B peptide mimic, B-YL) combined would stimulate lung maturation and block hyperoxia-induced neonatal lung injury more effectively than either modality alone. Pioglitazone 176-188 peroxisome proliferator-activated receptor gamma Rattus norvegicus 156-166 29428947-4 2018 OBJECTIVES: Since PPAR-gamma agonists have been demonstrated to promote neonatal lung maturation and injury repair, we hypothesized that a formulation of a PPAR-gamma agonist, pioglitazone (PGZ) and a synthetic lung surfactant (a surfactant protein B peptide mimic, B-YL) combined would stimulate lung maturation and block hyperoxia-induced neonatal lung injury more effectively than either modality alone. Pioglitazone 190-193 peroxisome proliferator-activated receptor gamma Rattus norvegicus 18-28 29428947-4 2018 OBJECTIVES: Since PPAR-gamma agonists have been demonstrated to promote neonatal lung maturation and injury repair, we hypothesized that a formulation of a PPAR-gamma agonist, pioglitazone (PGZ) and a synthetic lung surfactant (a surfactant protein B peptide mimic, B-YL) combined would stimulate lung maturation and block hyperoxia-induced neonatal lung injury more effectively than either modality alone. Pioglitazone 190-193 peroxisome proliferator-activated receptor gamma Rattus norvegicus 156-166 29428947-9 2018 CONCLUSIONS: Nebulized PPAR-gamma agonist PGZ with a synthetic lung surfactant accelerates lung maturation and prevents neonatal hyperoxia-induced lung injury more than either modality alone, with the potential to provide more effective prevention of BPD. Pioglitazone 42-45 peroxisome proliferator-activated receptor gamma Rattus norvegicus 23-33 28969989-4 2017 Pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, exerts anti-angiogenesis effect. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 16-64 28294376-0 2017 Influence of the pharmacokinetic profile on the plasma glucose lowering effect of the PPARgamma agonist pioglitazone in Wistar fatty rats. Pioglitazone 104-116 peroxisome proliferator-activated receptor gamma Rattus norvegicus 86-95 28649126-11 2017 Pre-treatment with a PPAR-gamma agonist pioglitazone (500 g/kg, ig) reversed LPS/cis-SG-induced liver injury, which was associated with inhibiting the nuclear factor kappa B (NF-kappaB) pathway. Pioglitazone 40-52 peroxisome proliferator-activated receptor gamma Rattus norvegicus 21-31 28810524-11 2017 Pioglitazone treatment significantly increased urinary calcium, serum TRAP, mRNA expression of RANKL, PPAR-gamma as well as significantly decreased Runx2, OPG, osteocalcin and AMPK levels in diabetic rats. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 102-112 28294376-3 2017 Pioglitazone hydrochloride, the PPARgamma agonist, was administered orally to Wistar fatty rats once a day (q.d.) Pioglitazone 0-26 peroxisome proliferator-activated receptor gamma Rattus norvegicus 32-41 28860994-1 2017 Pioglitazone is a type of peroxisome proliferator-activated receptor gamma (PPARgamma) agonist and has been demonstrated to be effective in chronic kidney diseases (CKD) treatment. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 26-74 28419516-14 2017 In another experiment, concurrent ip administration of non-effective dose of simvastatin (5 mg/kg) with pioglitazone (PPARgamma agonist; 10, 20 mg/kg) produced antinociception. Pioglitazone 104-116 peroxisome proliferator-activated receptor gamma Rattus norvegicus 118-127 28860994-1 2017 Pioglitazone is a type of peroxisome proliferator-activated receptor gamma (PPARgamma) agonist and has been demonstrated to be effective in chronic kidney diseases (CKD) treatment. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 76-85 27895156-4 2017 PPAR-gamma agonists, like pioglitazone, appear antiproteinuric. Pioglitazone 26-38 peroxisome proliferator-activated receptor gamma Rattus norvegicus 0-10 28286124-2 2017 This study aimed to evaluate the involvement of PPARgamma and NO pathway in the systemic and peripheral antinociceptive effect pioglitazone (Pio) using formalin test in rats. Pioglitazone 127-139 peroxisome proliferator-activated receptor gamma Rattus norvegicus 48-57 28286124-24 2017 Our data suggest that local and systemic antinociceptive activity of pioglitazone is mediated partly through PPARgamma in collaboration with NO pathway. Pioglitazone 69-81 peroxisome proliferator-activated receptor gamma Rattus norvegicus 109-118 27895156-6 2017 Treatment with sildenafil, the cGMP derivative 8-bromoguanosine 3",5"-cyclic monophosphate sodium salt (8-Br-cGMP), or pioglitazone dose-dependently downregulated podocyte injury-induced TRPC6 expression in vitro Knockdown or application of antagonists of PKG or PPAR-gamma enhanced TRPC6 expression in podocytes and counteracted effects of sildenafil and 8-Br-cGMP. Pioglitazone 119-131 peroxisome proliferator-activated receptor gamma Rattus norvegicus 263-273 28447730-8 2017 Treatment with pioglitazone ameliorated Abeta42 deposition in the hippocampus by increasing IDE and PPARgamma expression. Pioglitazone 15-27 peroxisome proliferator-activated receptor gamma Rattus norvegicus 100-109 28447730-9 2017 Notably, activation of the PI3K/AKT/GSK3beta pathway was also demonstrated to serve a role in pioglitazone-induced Abeta42 degradation, which was abrogated by the PPARgamma antagonist GW9662. Pioglitazone 94-106 peroxisome proliferator-activated receptor gamma Rattus norvegicus 163-172 27973471-0 2017 Peroxisome proliferator-activated receptor-gamma agonist pioglitazone reduces the development of necrotizing enterocolitis in a neonatal preterm rat model. Pioglitazone 57-69 peroxisome proliferator-activated receptor gamma Rattus norvegicus 0-48 27973471-2 2017 We hypothesized that the PPARgamma agonist pioglitazone (PIO) might be effective in preventing the development of NEC and/or reducing its severity. Pioglitazone 43-55 peroxisome proliferator-activated receptor gamma Rattus norvegicus 25-34 27973471-2 2017 We hypothesized that the PPARgamma agonist pioglitazone (PIO) might be effective in preventing the development of NEC and/or reducing its severity. Pioglitazone 57-60 peroxisome proliferator-activated receptor gamma Rattus norvegicus 25-34 28191533-8 2016 RESULTS: The current studies demonstrate: 1) that low, pharmacologically relevant, doses of the PPARgamma agonists effectively inhibit cyst growth; 2) there is a class action of the drugs with both commercially available PPARgamma agonists, rosiglitazone, and pioglitazone, inhibiting cyst growth; 3) the drugs showed efficacy in two different preclinical cystic models. Pioglitazone 260-272 peroxisome proliferator-activated receptor gamma Rattus norvegicus 96-105 27142118-2 2017 Recently, the peroxisome proliferation-activated receptor gamma (PPARgamma) agonist pioglitazone has been demonstrated to be neuroprotective in animal models of neurodegeneration. Pioglitazone 84-96 peroxisome proliferator-activated receptor gamma Rattus norvegicus 14-63 27142118-2 2017 Recently, the peroxisome proliferation-activated receptor gamma (PPARgamma) agonist pioglitazone has been demonstrated to be neuroprotective in animal models of neurodegeneration. Pioglitazone 84-96 peroxisome proliferator-activated receptor gamma Rattus norvegicus 65-74 27714428-2 2017 We recently demonstrated that activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by pioglitazone reduces the motivation for heroin and attenuates its rewarding properties. Pioglitazone 108-120 peroxisome proliferator-activated receptor gamma Rattus norvegicus 44-92 27714428-2 2017 We recently demonstrated that activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by pioglitazone reduces the motivation for heroin and attenuates its rewarding properties. Pioglitazone 108-120 peroxisome proliferator-activated receptor gamma Rattus norvegicus 94-103 27714428-9 2017 RESULTS: Data show that chronic and acute administration of pioglitazone attenuates morphine withdrawal symptoms, and these effects are mediated by activation of PPARgamma receptors. Pioglitazone 60-72 peroxisome proliferator-activated receptor gamma Rattus norvegicus 162-171 27714428-10 2017 Activation of PPARgamma by pioglitazone also abolishes yohimbine-induced reinstatement of heroin seeking and reduces heroin-induced reinstatement, while it does not affect cue-induced relapse. Pioglitazone 27-39 peroxisome proliferator-activated receptor gamma Rattus norvegicus 14-23 27973395-0 2016 Pioglitazone, a Peroxisome Proliferator-Activated Receptor gamma Agonist, Suppresses Rat Prostate Carcinogenesis. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 16-64 27973395-1 2016 Pioglitazone (PGZ), a peroxisome proliferator-activated receptor gamma agonist, which is known as a type 2 diabetes drug, inhibits cell proliferation in various cancer cell lines, including prostate carcinomas. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 22-70 27973395-1 2016 Pioglitazone (PGZ), a peroxisome proliferator-activated receptor gamma agonist, which is known as a type 2 diabetes drug, inhibits cell proliferation in various cancer cell lines, including prostate carcinomas. Pioglitazone 14-17 peroxisome proliferator-activated receptor gamma Rattus norvegicus 22-70 27262216-9 2016 It may be concluded that ruthenium red, a ryanodine receptor antagonist and pioglitazone, a PPAR-gamma agonist may be considered as potent pharmacological agent for the management of PaD induced endothelial dysfunction and subsequent vascular dementia. Pioglitazone 76-88 peroxisome proliferator-activated receptor gamma Rattus norvegicus 92-102 27777867-5 2016 Subsequently, molecular docking was carried out to determine the binding efficiency of curcumin as agonist of PPARgamma showed high affinity compared to pioglitazone. Pioglitazone 153-165 peroxisome proliferator-activated receptor gamma Rattus norvegicus 110-119 27698768-2 2016 The present study aimed to examine the modulation of neuroimmune activation in the spinal cord by the synthetic peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist, pioglitazone (Pio), in a rat model of neuropathic pain induced by chronic constriction injury (CCI). Pioglitazone 183-195 peroxisome proliferator-activated receptor gamma Rattus norvegicus 112-160 27698768-2 2016 The present study aimed to examine the modulation of neuroimmune activation in the spinal cord by the synthetic peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist, pioglitazone (Pio), in a rat model of neuropathic pain induced by chronic constriction injury (CCI). Pioglitazone 183-195 peroxisome proliferator-activated receptor gamma Rattus norvegicus 162-172 27698768-2 2016 The present study aimed to examine the modulation of neuroimmune activation in the spinal cord by the synthetic peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist, pioglitazone (Pio), in a rat model of neuropathic pain induced by chronic constriction injury (CCI). Pioglitazone 197-200 peroxisome proliferator-activated receptor gamma Rattus norvegicus 112-160 27698768-2 2016 The present study aimed to examine the modulation of neuroimmune activation in the spinal cord by the synthetic peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist, pioglitazone (Pio), in a rat model of neuropathic pain induced by chronic constriction injury (CCI). Pioglitazone 197-200 peroxisome proliferator-activated receptor gamma Rattus norvegicus 162-172 27376854-1 2016 This study aimed to assess the interaction between anti-inflammatory effects of pioglitazone (peroxysome proliferator activated receptor-gamma (PPARgamma) agonist, PGL), and indomethacin (cyclooxygenase (COX) inhibitor, IND) and to evaluate the possible underlying mechanisms. Pioglitazone 80-92 peroxisome proliferator-activated receptor gamma Rattus norvegicus 94-142 28191533-8 2016 RESULTS: The current studies demonstrate: 1) that low, pharmacologically relevant, doses of the PPARgamma agonists effectively inhibit cyst growth; 2) there is a class action of the drugs with both commercially available PPARgamma agonists, rosiglitazone, and pioglitazone, inhibiting cyst growth; 3) the drugs showed efficacy in two different preclinical cystic models. Pioglitazone 260-272 peroxisome proliferator-activated receptor gamma Rattus norvegicus 221-230 27046338-2 2016 We investigated whether chronic peroxisome proliferator-activated receptor gamma agonism with pioglitazone can prevent the development of HFpEF. Pioglitazone 94-106 peroxisome proliferator-activated receptor gamma Rattus norvegicus 32-80 27389824-3 2016 Pioglitazone, a peroxisome proliferated-activated receptor-gamma (PPAR-gamma) agonist, was previously reported to enhance cognition through its effect on Abeta accumulation and clearance. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 16-64 27389824-3 2016 Pioglitazone, a peroxisome proliferated-activated receptor-gamma (PPAR-gamma) agonist, was previously reported to enhance cognition through its effect on Abeta accumulation and clearance. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 66-76 27175924-5 2016 Exogenous application of pioglitazone, a PPARgamma agonist, reduced the p-Drp1(Ser616) expression, decreased TGI-induced oxidative stress and activated caspase-3 expression, lessened the extents of DNA fragmentation, and diminished the numbers of TUNEL-positive neuronal cells; all of these effects were reversed by GW9662, a PPARgamma antagonist. Pioglitazone 25-37 peroxisome proliferator-activated receptor gamma Rattus norvegicus 41-50 27175924-5 2016 Exogenous application of pioglitazone, a PPARgamma agonist, reduced the p-Drp1(Ser616) expression, decreased TGI-induced oxidative stress and activated caspase-3 expression, lessened the extents of DNA fragmentation, and diminished the numbers of TUNEL-positive neuronal cells; all of these effects were reversed by GW9662, a PPARgamma antagonist. Pioglitazone 25-37 peroxisome proliferator-activated receptor gamma Rattus norvegicus 326-335 27190792-1 2016 INTRODUCTION: The present study was taken up to compare and evaluate the effect of Momordica charantia supplementation with pioglitazone on PKC-beta and PPAR-gamma activity in kidneys of diabetic rats. Pioglitazone 124-136 peroxisome proliferator-activated receptor gamma Rattus norvegicus 153-163 25534548-1 2015 Pioglitazone, the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist is an effective therapy for type 2 diabetes, but has been associated with increased risk for bone fracture. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 18-66 26825545-4 2016 In the present study, we administered pioglitazone, a PPARgamma agonist, to high-fat fed rats, and measured their FA composition of triglyceride fraction in adipose tissue and adipocyte diameters in pioglitazone-treated (PIO) and non-treated (control) rats. Pioglitazone 38-50 peroxisome proliferator-activated receptor gamma Rattus norvegicus 54-63 26721358-0 2016 Ameliorative potential of pioglitazone and ceftriaxone alone and in combination in rat model of neuropathic pain: Targeting PPARgamma and GLT-1 pathways. Pioglitazone 26-38 peroxisome proliferator-activated receptor gamma Rattus norvegicus 124-133 26721358-2 2016 Present study has been designed to elucidate the interaction between the GLT-1 activator (ceftriaxone) and PPAR gamma agonist (pioglitazone) in the spinal nerve ligation induced neuropathic pain. Pioglitazone 127-139 peroxisome proliferator-activated receptor gamma Rattus norvegicus 107-117 26536032-7 2015 Immunostaining showed that renal expressions of PPARalpha and PPARgamma were reduced by cisplatin and restored to vehicle-treated values after simultaneous treatment with pioglitazone or fenofibrate. Pioglitazone 171-183 peroxisome proliferator-activated receptor gamma Rattus norvegicus 62-71 26742933-4 2016 We hypothesized that treatment of this condition with the peroxisome proliferator-activated receptor-gamma (PPARgamma) activator pioglitazone, known to regulate the expression of different genes addressing insulin resistance, inflammatory changes, and vascular remodelling, could be a beneficial approach. Pioglitazone 129-141 peroxisome proliferator-activated receptor gamma Rattus norvegicus 58-106 26742933-4 2016 We hypothesized that treatment of this condition with the peroxisome proliferator-activated receptor-gamma (PPARgamma) activator pioglitazone, known to regulate the expression of different genes addressing insulin resistance, inflammatory changes, and vascular remodelling, could be a beneficial approach. Pioglitazone 129-141 peroxisome proliferator-activated receptor gamma Rattus norvegicus 108-117 26742933-15 2016 Based on the beneficial impact of pioglitazone, activation of PPARgamma might be a promising treatment option in PAH. Pioglitazone 34-46 peroxisome proliferator-activated receptor gamma Rattus norvegicus 62-71 26495791-2 2016 METHODS: AR42j cells pretreated with the peroxisome proliferator-activated receptor-gamma agonist pioglitazone were activated by cerulein as an in vitro model of acute pancreatitis. Pioglitazone 98-110 peroxisome proliferator-activated receptor gamma Rattus norvegicus 41-89 26927377-0 2016 [Pioglitazone decreases the levels of inflammatory cytokines in SD rats with traumatic brain injury via up-regulating PPARgamma]. Pioglitazone 1-13 peroxisome proliferator-activated receptor gamma Rattus norvegicus 118-127 26927377-1 2016 OBJECTIVE: To observe the effect of pioglitazone on the levels of peroxisome proliferator activated receptor gamma (PPARgamma), tumor necrosis factor-alpha (TNF-alpha) and interleukin 6 (IL-6) mRNAs and the dose-dependent relationship in rats with traumatic brain injury (TBI). Pioglitazone 36-48 peroxisome proliferator-activated receptor gamma Rattus norvegicus 66-114 26927377-1 2016 OBJECTIVE: To observe the effect of pioglitazone on the levels of peroxisome proliferator activated receptor gamma (PPARgamma), tumor necrosis factor-alpha (TNF-alpha) and interleukin 6 (IL-6) mRNAs and the dose-dependent relationship in rats with traumatic brain injury (TBI). Pioglitazone 36-48 peroxisome proliferator-activated receptor gamma Rattus norvegicus 116-125 26927377-5 2016 RESULTS: Twenty-four hours after the injury, the expression of PPARgamma mRNA was up-regulated significantly in all pioglitazone groups, with significant difference between each pioglitazone group in a dose-dependent manner. Pioglitazone 116-128 peroxisome proliferator-activated receptor gamma Rattus norvegicus 63-72 26927377-5 2016 RESULTS: Twenty-four hours after the injury, the expression of PPARgamma mRNA was up-regulated significantly in all pioglitazone groups, with significant difference between each pioglitazone group in a dose-dependent manner. Pioglitazone 178-190 peroxisome proliferator-activated receptor gamma Rattus norvegicus 63-72 26927377-8 2016 CONCLUSION: Pioglitazone inhibits inflammatory reaction by up-regulating the level of PPARgamma mRNA and down-regulating the levels of TNF-alpha and IL-6 mRNAs in rats with TBI. Pioglitazone 12-24 peroxisome proliferator-activated receptor gamma Rattus norvegicus 86-95 28116157-6 2016 The results of present study showed that, similar to Vit E, both rosiglitazone and pioglitazone as PPARgamma agonists exerted protective effects against cerebellar tissues oxidative damage in hypothyroid rats. Pioglitazone 83-95 peroxisome proliferator-activated receptor gamma Rattus norvegicus 99-108 27110236-2 2016 This study was to investigate whether pioglitazone (PIO), a PPARgamma agonist, could protect against pressure overload-induced cardiac hypertrophy. Pioglitazone 38-50 peroxisome proliferator-activated receptor gamma Rattus norvegicus 60-69 27110236-2 2016 This study was to investigate whether pioglitazone (PIO), a PPARgamma agonist, could protect against pressure overload-induced cardiac hypertrophy. Pioglitazone 52-55 peroxisome proliferator-activated receptor gamma Rattus norvegicus 60-69 26558146-11 2015 The majority of the experimental studies is on pioglitazone and rosiglitazone, which are PPARgamma activators. Pioglitazone 47-59 peroxisome proliferator-activated receptor gamma Rattus norvegicus 89-98 25534548-1 2015 Pioglitazone, the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist is an effective therapy for type 2 diabetes, but has been associated with increased risk for bone fracture. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 68-78 26163452-3 2015 The peroxisome proliferator-activated receptor gamma agonist, pioglitazone, is known to exert antiinflammatory and reno-protective effects in various kidney injuries. Pioglitazone 62-74 peroxisome proliferator-activated receptor gamma Rattus norvegicus 4-52 26394827-2 2015 The aim of this study was to explore the effects of oral administration of the pioglitazone, the peroxisome proliferator activated receptor gamma (PPAR-gamma) agonist, on the morphine-induced neuroinflammation in the lumbar region of the male Wistar rat spinal cord. Pioglitazone 79-91 peroxisome proliferator-activated receptor gamma Rattus norvegicus 97-145 26394827-2 2015 The aim of this study was to explore the effects of oral administration of the pioglitazone, the peroxisome proliferator activated receptor gamma (PPAR-gamma) agonist, on the morphine-induced neuroinflammation in the lumbar region of the male Wistar rat spinal cord. Pioglitazone 79-91 peroxisome proliferator-activated receptor gamma Rattus norvegicus 147-157 26101342-4 2015 Sprague-Dawley rats received a 2-week subcutaneous infusion of angiotensin II (120 ng/kg per minute) combined with a continuous intracerebroventricular infusion of vehicle, the PPAR-gamma agonist pioglitazone (3 nmol/h) or the PPAR-gamma antagonist GW9662 (7 nmol/h). Pioglitazone 196-208 peroxisome proliferator-activated receptor gamma Rattus norvegicus 177-187 26101342-9 2015 These responses to angiotensin II were exacerbated by GW9662 and ameliorated by pioglitazone, which increased PPAR-gamma mRNA and PPAR-gamma DNA-binding activity in subfornical organ and hypothalamic paraventricular nucleus. Pioglitazone 80-92 peroxisome proliferator-activated receptor gamma Rattus norvegicus 110-120 26101342-9 2015 These responses to angiotensin II were exacerbated by GW9662 and ameliorated by pioglitazone, which increased PPAR-gamma mRNA and PPAR-gamma DNA-binding activity in subfornical organ and hypothalamic paraventricular nucleus. Pioglitazone 80-92 peroxisome proliferator-activated receptor gamma Rattus norvegicus 130-140 25891824-9 2015 Therefore, the mTOR signaling pathway was activated in the PTZ-induced SE rat model, and the PPAR-gamma agonist, pioglitazone, had a neuroprotective effect, by inhibiting activation of the mTOR pathway and preventing the increase in the levels of IL-1beta and IL-6. Pioglitazone 113-125 peroxisome proliferator-activated receptor gamma Rattus norvegicus 93-103 26186541-6 2015 Because of the delayed upregulation of CB2R and IBA1, we next treated animals daily with CB2R agonist AM1241 or anti-inflammatory PPAR-gamma agonist pioglitazone from 2 to 5 days after MCAo. Pioglitazone 149-161 peroxisome proliferator-activated receptor gamma Rattus norvegicus 130-140 25611692-0 2015 Peroxisome proliferator-activated receptor-gamma agonist pioglitazone ameliorates white matter lesion and cognitive impairment in hypertensive rats. Pioglitazone 57-69 peroxisome proliferator-activated receptor gamma Rattus norvegicus 0-48 25579788-0 2015 A single dose of PPARgamma agonist pioglitazone reduces cortical oxidative damage and microglial reaction following lateral fluid percussion brain injury in rats. Pioglitazone 35-47 peroxisome proliferator-activated receptor gamma Rattus norvegicus 17-26 25900064-6 2015 PPAR-gamma gene expression was significantly increased by compound 5m (2.00-fold) in comparison to the standard drugs pioglitazone (1.5-fold) and rosiglitazone (1.0-fold). Pioglitazone 118-130 peroxisome proliferator-activated receptor gamma Rattus norvegicus 0-10 25772146-2 2015 In this study, we examined the role of pioglitazone, an agonist of peroxisome proliferator-activated receptor gamma, in gut barrier failure during experimental peritonitis in rats. Pioglitazone 39-51 peroxisome proliferator-activated receptor gamma Rattus norvegicus 67-115 25801003-3 2015 The aim of this study was to determine the impact of activation of PPARgamma and increased incretin action via dipeptidyl-peptidase inhibition using pioglitazone and/or alogliptin, respectively, on islet lipid metabolism in prediabetic and diabetic ZDF rats. Pioglitazone 149-161 peroxisome proliferator-activated receptor gamma Rattus norvegicus 67-76 25854775-0 2015 Modulation of the Nitrergic Pathway via Activation of PPAR-gamma Contributes to the Neuroprotective Effect of Pioglitazone Against Streptozotocin-Induced Memory Dysfunction. Pioglitazone 110-122 peroxisome proliferator-activated receptor gamma Rattus norvegicus 54-64 25611692-3 2015 We investigated whether peroxisome proliferator-activated receptor-gamma agonist pioglitazone, with properties of vascular protection and antiinflammation, exerts beneficial effect in hypertensive WML rats. Pioglitazone 81-93 peroxisome proliferator-activated receptor gamma Rattus norvegicus 24-72 24504689-2 2015 PURPOSE: The purpose of the present study was to investigate the effects of the acute administration of pioglitazone, a selective agonist of peroxisome proliferator activated receptors gamma (PPAR-gamma), on the morphine withdrawal syndrome in the rat. Pioglitazone 104-116 peroxisome proliferator-activated receptor gamma Rattus norvegicus 141-190 25523934-2 2015 The mechanism underlying the effect of peroxisome proliferator-activated receptor gamma (PPARgamma) agonist pioglitazone (PIO) on RAGE expression in coronary artery smooth muscle cells (SMCs) stimulated by high glucose concentrations remains to be elucidated. Pioglitazone 108-120 peroxisome proliferator-activated receptor gamma Rattus norvegicus 39-87 25523934-2 2015 The mechanism underlying the effect of peroxisome proliferator-activated receptor gamma (PPARgamma) agonist pioglitazone (PIO) on RAGE expression in coronary artery smooth muscle cells (SMCs) stimulated by high glucose concentrations remains to be elucidated. Pioglitazone 108-120 peroxisome proliferator-activated receptor gamma Rattus norvegicus 89-98 25807446-14 2015 Gene expression of PPAR-gamma, adiponectin, LPL and C/EBP-alpha from cachectic rats was upregulated after PGZ. Pioglitazone 106-109 peroxisome proliferator-activated receptor gamma Rattus norvegicus 19-29 24504689-2 2015 PURPOSE: The purpose of the present study was to investigate the effects of the acute administration of pioglitazone, a selective agonist of peroxisome proliferator activated receptors gamma (PPAR-gamma), on the morphine withdrawal syndrome in the rat. Pioglitazone 104-116 peroxisome proliferator-activated receptor gamma Rattus norvegicus 192-202 24504689-9 2015 It seems that pioglitazone suppresses morphine withdrawal syndrome through PPAR-gamma independent mechanisms. Pioglitazone 14-26 peroxisome proliferator-activated receptor gamma Rattus norvegicus 75-85 25671601-1 2015 Pioglitazone (PIO) is a peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist in clinical use for treatment of type 2 diabetes (T2DM). Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 24-72 25599238-0 2015 Pioglitazone rapidly reduces neuropathic pain through astrocyte and nongenomic PPARgamma mechanisms. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 79-88 25599238-4 2015 injection of pioglitazone, a PPARgamma agonist, reduced hyperalgesia within 30 minutes, a time frame that is typically less than that required for genomic mechanisms. Pioglitazone 13-25 peroxisome proliferator-activated receptor gamma Rattus norvegicus 29-38 25599238-5 2015 To determine the very rapid antihyperalgesic actions of PPARgamma activation, we administered pioglitazone to rats with spared nerve injury and evaluated hyperalgesia. Pioglitazone 94-106 peroxisome proliferator-activated receptor gamma Rattus norvegicus 56-65 25599238-9 2015 pioglitazone, suggesting a spinal PPARgamma-dependent mechanism. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 34-43 25599238-15 2015 We conclude that acute pioglitazone inhibits neuropathic pain in part by reducing astrocyte activation and through both genomic and nongenomic PPARgamma mechanisms. Pioglitazone 23-35 peroxisome proliferator-activated receptor gamma Rattus norvegicus 143-152 25671601-1 2015 Pioglitazone (PIO) is a peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist in clinical use for treatment of type 2 diabetes (T2DM). Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 74-83 25671601-1 2015 Pioglitazone (PIO) is a peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist in clinical use for treatment of type 2 diabetes (T2DM). Pioglitazone 14-17 peroxisome proliferator-activated receptor gamma Rattus norvegicus 24-72 25671601-1 2015 Pioglitazone (PIO) is a peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist in clinical use for treatment of type 2 diabetes (T2DM). Pioglitazone 14-17 peroxisome proliferator-activated receptor gamma Rattus norvegicus 74-83 25490415-0 2014 Activation of PPAR-gamma by pioglitazone attenuates oxidative stress in aging rat cerebral arteries through upregulating UCP2. Pioglitazone 28-40 peroxisome proliferator-activated receptor gamma Rattus norvegicus 14-24 26156624-3 2015 In the current study, we analyzed whether pioglitazone, an agonist of PPARgamma, reduces angiotensin II-induced vascular lipid accumulation. Pioglitazone 42-54 peroxisome proliferator-activated receptor gamma Rattus norvegicus 70-79 25490415-3 2014 Pioglitazone, a well-known PPAR-gamma agonist, protects against oxidative stress in the rostral ventrolateral medulla by the upregulation of mitochondrial uncoupling protein 2 (UCP2). Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 27-37 25490415-7 2014 One-month pioglitazone administration also restored PPAR-gamma expression and increased the levels of UCP2 in aging rat cerebral arteries. Pioglitazone 10-22 peroxisome proliferator-activated receptor gamma Rattus norvegicus 52-62 25490415-10 2014 Our study demonstrated that the activation of PPAR-gamma by pioglitazone protected against oxidative stress damage in aging cerebral arteries by upregulating UCP2. Pioglitazone 60-72 peroxisome proliferator-activated receptor gamma Rattus norvegicus 46-56 25086044-4 2014 We hypothesized that pioglitazone, a peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, would normalize retinal insulin signal transduction through reduced tumor necrosis factor alpha (TNFalpha) and suppressor of cytokine signaling 3 (SOCS3) activities in whole retina and retinal endothelial cells (REC) and Muller cells. Pioglitazone 21-33 peroxisome proliferator-activated receptor gamma Rattus norvegicus 37-85 25086044-4 2014 We hypothesized that pioglitazone, a peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, would normalize retinal insulin signal transduction through reduced tumor necrosis factor alpha (TNFalpha) and suppressor of cytokine signaling 3 (SOCS3) activities in whole retina and retinal endothelial cells (REC) and Muller cells. Pioglitazone 21-33 peroxisome proliferator-activated receptor gamma Rattus norvegicus 87-96 25028387-12 2014 Finally, pharmacological inhibition of Egr-1 with pioglitazone, a peroxisome proliferator activated receptor-gamma ligand, attenuated vascular remodelling including the development of neointimal lesions. Pioglitazone 50-62 peroxisome proliferator-activated receptor gamma Rattus norvegicus 66-114 25177938-0 2014 PPAR-gamma agonist pioglitazone affects rat gouty arthritis by regulating cytokines. Pioglitazone 19-31 peroxisome proliferator-activated receptor gamma Rattus norvegicus 0-10 24899385-2 2014 The purpose of the present study is to investigate the effects of pioglitazone, a peroxisome proliferator-activated receptors gamma (PPAR-gamma) agonist, on the morphine-induced tolerance and dependence. Pioglitazone 66-78 peroxisome proliferator-activated receptor gamma Rattus norvegicus 133-143 25177938-1 2014 The objective was to study peroxisome proliferator-activated receptor gamma (PPARgamma) agonist pioglitazone regulation effect and its mechanism of expression of cytokines on acute gouty arthritis synovial in rats. Pioglitazone 96-108 peroxisome proliferator-activated receptor gamma Rattus norvegicus 27-75 25177938-1 2014 The objective was to study peroxisome proliferator-activated receptor gamma (PPARgamma) agonist pioglitazone regulation effect and its mechanism of expression of cytokines on acute gouty arthritis synovial in rats. Pioglitazone 96-108 peroxisome proliferator-activated receptor gamma Rattus norvegicus 77-86 24771068-0 2014 Protective effect of pioglitazone, a PPARgamma agonist against acetaminophen-induced hepatotoxicity in rats. Pioglitazone 21-33 peroxisome proliferator-activated receptor gamma Rattus norvegicus 37-46 24771068-3 2014 Pioglitazone, PPARgamma ligand, is clinically tested and used in treatment of diabetes. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 14-23 23830318-3 2014 Pioglitazone, a PPARgamma agonist, was administered in a rat model of spinal cord ischemia, and the extent of neurological damage and histological alterations were assessed. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 16-25 26455221-1 2014 OBJECTIVE: To investigate the effect of pharmacologic delay with pioglitazone, a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist, on extended perforator flap survival in a rat model. Pioglitazone 65-77 peroxisome proliferator-activated receptor gamma Rattus norvegicus 81-129 26455221-1 2014 OBJECTIVE: To investigate the effect of pharmacologic delay with pioglitazone, a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist, on extended perforator flap survival in a rat model. Pioglitazone 65-77 peroxisome proliferator-activated receptor gamma Rattus norvegicus 131-141 24277156-2 2014 The current study was carried out to investigate the effects of chronic administration of pioglitazone, a PPAR-gamma agonist, on cognitive impairment in an animal model of Alzheimer"s disease induced by beta-amyloid. Pioglitazone 90-102 peroxisome proliferator-activated receptor gamma Rattus norvegicus 106-116 24277156-9 2014 However, pretreatment with PPAR-gamma antagonist BADGE (15 mg/kg) with higher dose of pioglitazone significantly reversed its protective action in memory impairment in betaA-treated rats, which indicates the involvement of PPAR-gamma receptors mediating neuroprotective action. Pioglitazone 86-98 peroxisome proliferator-activated receptor gamma Rattus norvegicus 27-37 24277156-9 2014 However, pretreatment with PPAR-gamma antagonist BADGE (15 mg/kg) with higher dose of pioglitazone significantly reversed its protective action in memory impairment in betaA-treated rats, which indicates the involvement of PPAR-gamma receptors mediating neuroprotective action. Pioglitazone 86-98 peroxisome proliferator-activated receptor gamma Rattus norvegicus 223-233 24793312-9 2014 In addition, pretreatment with 10 mumol/L PPARgamma agonist pioglitazone was more effective in protecting CGCs against B27 deprivation-induced apoptosis, whereas pretreatment with 20 mumol/L PPARgamma antagonist GW9662 abolished all the effects of telmisartan in CGCs deprived of B27. Pioglitazone 60-72 peroxisome proliferator-activated receptor gamma Rattus norvegicus 42-51 24530596-2 2014 Since peroxisome proliferator-activated receptor gamma (PPARgamma) agonists like pioglitazone (PIO) regulate inflammatory response and inhibit angiogenesis in endothelial cells, we evaluated PIO as treatment for experimental portal hypertension. Pioglitazone 81-93 peroxisome proliferator-activated receptor gamma Rattus norvegicus 6-54 24530596-2 2014 Since peroxisome proliferator-activated receptor gamma (PPARgamma) agonists like pioglitazone (PIO) regulate inflammatory response and inhibit angiogenesis in endothelial cells, we evaluated PIO as treatment for experimental portal hypertension. Pioglitazone 81-93 peroxisome proliferator-activated receptor gamma Rattus norvegicus 56-65 24582928-0 2014 Pioglitazone, a PPARgamma agonist, provides comparable protection to angiotensin converting enzyme inhibitor ramipril against adriamycin nephropathy in rat. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 16-25 24582928-8 2014 These results demonstrate that in a nondiabetic renal disease, such as adriamycin-induced nephropathy, PPARgamma agonist pioglitazone provides renoprotection to a similar extent as an ACE inhibitor by interfering with the expression of local RAS components and attenuating related profibrotic and inflammatory mechanisms. Pioglitazone 121-133 peroxisome proliferator-activated receptor gamma Rattus norvegicus 103-112 23830318-12 2014 CONCLUSIONS: PPARgamma agonist pioglitazone pretreatment significantly reduces infarct volume and attenuates neurological deficits following spinal cord ischemia. Pioglitazone 31-43 peroxisome proliferator-activated receptor gamma Rattus norvegicus 13-22 24589595-0 2014 [Effects of pioglitazone on myocardial peroxisome proliferator-activated receptor gamma co-activator lalpha expression in rats with myocardial ischemia/reperfusion injury]. Pioglitazone 12-24 peroxisome proliferator-activated receptor gamma Rattus norvegicus 39-87 24589595-1 2014 OBJECTIVE: To investigate the effects of pioglitazone on the expression of peroxisome proliferator-activated receptor gamma co-activator lalpha (PGC-lalpha) in rat myocardium following myocardial ischemia/reperfusion (I/R) injury. Pioglitazone 41-53 peroxisome proliferator-activated receptor gamma Rattus norvegicus 75-123 24589595-6 2014 CONCLUSION: Pioglitazone can inhibit myocardial apoptosis induced by I/R injury and up-regulate myocardial PGC-lalpha expression, and these effects are mediated by PPARgamma. Pioglitazone 12-24 peroxisome proliferator-activated receptor gamma Rattus norvegicus 164-173 24928921-5 2014 OBJECTIVE: To compare the anti-arthritic potencies of a PPAR-alpha agonist (fenofibrate, a lipid lowering drug) and a PPAR-gamma agonist (pioglitazone, formerly used as an antidiabetic drug) in rat adjuvant-induced arthritis. Pioglitazone 138-150 peroxisome proliferator-activated receptor gamma Rattus norvegicus 118-128 24923291-2 2014 The new compound CLC-3000 is an aminoethyl nitrate (AEN) derivative of pioglitazone, a thiazolidinedione antidiabetic agent combining the peroxisome proliferator-activated receptor gamma agonist activity of pioglitazone with the NO-donating activity of the nitrate moiety. Pioglitazone 71-83 peroxisome proliferator-activated receptor gamma Rattus norvegicus 138-186 24164426-1 2013 Thiazolidinediones (TZDs) including rosiglitazone (RSG) and pioglitazone (PIO) are synthetic agonists selective for peroxisome proliferator-activated receptor-gamma (PPARgamma) and have been clinically used to treat type-II diabetes as insulin sensitizers. Pioglitazone 60-72 peroxisome proliferator-activated receptor gamma Rattus norvegicus 116-164 24164426-1 2013 Thiazolidinediones (TZDs) including rosiglitazone (RSG) and pioglitazone (PIO) are synthetic agonists selective for peroxisome proliferator-activated receptor-gamma (PPARgamma) and have been clinically used to treat type-II diabetes as insulin sensitizers. Pioglitazone 60-72 peroxisome proliferator-activated receptor gamma Rattus norvegicus 166-175 24164426-1 2013 Thiazolidinediones (TZDs) including rosiglitazone (RSG) and pioglitazone (PIO) are synthetic agonists selective for peroxisome proliferator-activated receptor-gamma (PPARgamma) and have been clinically used to treat type-II diabetes as insulin sensitizers. Pioglitazone 74-77 peroxisome proliferator-activated receptor gamma Rattus norvegicus 116-164 24164426-1 2013 Thiazolidinediones (TZDs) including rosiglitazone (RSG) and pioglitazone (PIO) are synthetic agonists selective for peroxisome proliferator-activated receptor-gamma (PPARgamma) and have been clinically used to treat type-II diabetes as insulin sensitizers. Pioglitazone 74-77 peroxisome proliferator-activated receptor gamma Rattus norvegicus 166-175 23982996-0 2013 The peroxisome proliferator-activated receptor gamma agonist pioglitazone preserves bone microarchitecture in experimental arthritis by reducing the interleukin-17-dependent osteoclastogenic pathway. Pioglitazone 61-73 peroxisome proliferator-activated receptor gamma Rattus norvegicus 4-52 23868339-5 2013 Since the development of pioglitazone, its risk assessment has suffered from several inaccuracies such as its alleged specificity for the male rat, untrustworthy selective agonism for PPARgamma and mistaken risk evaluation in the large PROactive trial (PROspective pioglitAzone Clinical Trial In macroVascular Events), where one case with a benign tumour in the placebo group was counted as a cancer case. Pioglitazone 25-37 peroxisome proliferator-activated receptor gamma Rattus norvegicus 184-193 24185678-2 2013 METHODS: Severe acute pancreatitis (SAP) and mild acute pancreatitis (MAP) were induced and pre-treated with pioglitazone, which is a ligand of PPAR-gamma. Pioglitazone 109-121 peroxisome proliferator-activated receptor gamma Rattus norvegicus 144-154 24185678-6 2013 RESULTS: Expression levels of PPAR-gamma proteins were elevated in the pancreases of SAP or MAP rats pre-injected with pioglitazone intraperitoneally. Pioglitazone 119-131 peroxisome proliferator-activated receptor gamma Rattus norvegicus 30-40 23550625-0 2013 Activation of PPARgamma by pioglitazone potentiates the effects of naltrexone on alcohol drinking and relapse in msP rats. Pioglitazone 27-39 peroxisome proliferator-activated receptor gamma Rattus norvegicus 14-23 23550625-1 2013 BACKGROUND: Pioglitazone is a selective peroxisome proliferator-activated receptor gamma (PPARgamma) agonist used for the treatment of insulin resistance and type 2 diabetes. Pioglitazone 12-24 peroxisome proliferator-activated receptor gamma Rattus norvegicus 40-88 23550625-1 2013 BACKGROUND: Pioglitazone is a selective peroxisome proliferator-activated receptor gamma (PPARgamma) agonist used for the treatment of insulin resistance and type 2 diabetes. Pioglitazone 12-24 peroxisome proliferator-activated receptor gamma Rattus norvegicus 90-99 23550625-2 2013 Previous studies conducted in our laboratory showed that activation of PPARgamma by pioglitazone reduces alcohol drinking, stress-induced relapse, and alcohol withdrawal syndrome in rats. Pioglitazone 84-96 peroxisome proliferator-activated receptor gamma Rattus norvegicus 71-80 23415633-5 2013 Blockade of PPARgamma with GW9662, an irreversible and selective PPARgamma antagonist, dose-dependently reduced the inhibitory effect of pioglitazone on hypersensitivity, indicating a PPARgamma-dependent action. Pioglitazone 137-149 peroxisome proliferator-activated receptor gamma Rattus norvegicus 12-21 22277574-2 2013 In the current study, we examined the effect of pioglitazone, an agonist of peroxisome proliferator activated receptor-gamma, on angiotensin II-induced intracardiac lipid accumulation and cardiac dysfunction. Pioglitazone 48-60 peroxisome proliferator-activated receptor gamma Rattus norvegicus 76-124 23415633-5 2013 Blockade of PPARgamma with GW9662, an irreversible and selective PPARgamma antagonist, dose-dependently reduced the inhibitory effect of pioglitazone on hypersensitivity, indicating a PPARgamma-dependent action. Pioglitazone 137-149 peroxisome proliferator-activated receptor gamma Rattus norvegicus 65-74 23415633-5 2013 Blockade of PPARgamma with GW9662, an irreversible and selective PPARgamma antagonist, dose-dependently reduced the inhibitory effect of pioglitazone on hypersensitivity, indicating a PPARgamma-dependent action. Pioglitazone 137-149 peroxisome proliferator-activated receptor gamma Rattus norvegicus 65-74 22981741-5 2013 In the present study, we aimed to investigate the effects of pioglitazone, a synthetic peroxisome proliferator-activated receptor-gamma agonist, on MMPs and oxidative stress in a renal IR injury model in rats. Pioglitazone 61-73 peroxisome proliferator-activated receptor gamma Rattus norvegicus 87-135 23298687-0 2013 Apoptosis rate and transcriptional response of pancreatic islets exposed to the PPAR gamma agonist Pioglitazone. Pioglitazone 99-111 peroxisome proliferator-activated receptor gamma Rattus norvegicus 80-90 23335111-1 2013 Pioglitazone (PGZ), a thiazolidinedione antidiabetic agent, is reported as a potent and selective activator of peroxisome proliferator-activated receptor gamma (PPAR gamma). Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 111-159 23335111-1 2013 Pioglitazone (PGZ), a thiazolidinedione antidiabetic agent, is reported as a potent and selective activator of peroxisome proliferator-activated receptor gamma (PPAR gamma). Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 161-171 23335111-1 2013 Pioglitazone (PGZ), a thiazolidinedione antidiabetic agent, is reported as a potent and selective activator of peroxisome proliferator-activated receptor gamma (PPAR gamma). Pioglitazone 14-17 peroxisome proliferator-activated receptor gamma Rattus norvegicus 111-159 23335111-1 2013 Pioglitazone (PGZ), a thiazolidinedione antidiabetic agent, is reported as a potent and selective activator of peroxisome proliferator-activated receptor gamma (PPAR gamma). Pioglitazone 14-17 peroxisome proliferator-activated receptor gamma Rattus norvegicus 161-171 23583338-3 2013 The current study aimed to determine the effects of a PPAR-gamma agonist pioglitazone on mechanical hyperalgesia and neuroimmune activation in a rat model of neuropathic pain induced by L5 spinal nerve transection (SNT). Pioglitazone 73-85 peroxisome proliferator-activated receptor gamma Rattus norvegicus 54-64 23583338-9 2013 In conclusion, pioglitazone ameliorates the mechanical hyperalgesia induced by L5 SNT via inhibiting the spinal neuroimmune activation in rats, suggesting spinal PPAR-gamma signaling pathway may be involved in the pathogenesis of mechanical hyperalgesia. Pioglitazone 15-27 peroxisome proliferator-activated receptor gamma Rattus norvegicus 162-172 23504801-0 2013 PPAR-gamma agonist pioglitazone prevents apoptosis of endothelial progenitor cells from rat bone marrow. Pioglitazone 19-31 peroxisome proliferator-activated receptor gamma Rattus norvegicus 0-10 23504801-2 2013 This study explores the effect of selective PPAR-gamma agonist, pioglitazone, on EPC apoptosis. Pioglitazone 64-76 peroxisome proliferator-activated receptor gamma Rattus norvegicus 44-54 23404530-2 2013 In the present study, we investigated the effects of pioglitazone, a peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, on HG-induced ECM accumulation and the underlying mechanism in rat PMCs (RPMCs). Pioglitazone 53-65 peroxisome proliferator-activated receptor gamma Rattus norvegicus 69-117 23404530-2 2013 In the present study, we investigated the effects of pioglitazone, a peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, on HG-induced ECM accumulation and the underlying mechanism in rat PMCs (RPMCs). Pioglitazone 53-65 peroxisome proliferator-activated receptor gamma Rattus norvegicus 119-128 23404530-4 2013 Pretreatment with pioglitazone not only decreased the expression of PAI-1 and matrix proteins (FN and collagen I), but prevented the downregulation of PPARgamma in RPMCs under HG conditions. Pioglitazone 18-30 peroxisome proliferator-activated receptor gamma Rattus norvegicus 151-160 23404530-8 2013 Collectively, these results suggest that pioglitazone inhibits HG-induced ECM accumulation in RPMCs by increasing PPARgamma expression, and by inhibiting the NF-kappaB and AP-1 pathways. Pioglitazone 41-53 peroxisome proliferator-activated receptor gamma Rattus norvegicus 114-123 24024139-6 2013 Moreover, pioglitazone-mediated induction of catalase activity in normal rat astrocytes was completely blocked by transfection with a PPARgamma-dominant negative plasmid. Pioglitazone 10-22 peroxisome proliferator-activated receptor gamma Rattus norvegicus 134-143 22613706-11 2012 Pioglitazone, a ligand of PPARgamma activating protein kinase A (PKA), significantly attenuated this delay by sorting Mrp2 into bile canalicular membranes. Pioglitazone 0-12 peroxisome proliferator-activated receptor gamma Rattus norvegicus 26-35 23527159-2 2013 Peroxisome proliferator-activated receptor gamma (PPARgamma) agonist pioglitazone previously used to treat type 2 diabetes mellitus (T2DM) has also been demonstrated to be effective in anti-inflammatory reaction and anti-oxidative stress in the animal models of AD and other neuroinflammatory diseases. Pioglitazone 69-81 peroxisome proliferator-activated receptor gamma Rattus norvegicus 0-48 23527159-2 2013 Peroxisome proliferator-activated receptor gamma (PPARgamma) agonist pioglitazone previously used to treat type 2 diabetes mellitus (T2DM) has also been demonstrated to be effective in anti-inflammatory reaction and anti-oxidative stress in the animal models of AD and other neuroinflammatory diseases. Pioglitazone 69-81 peroxisome proliferator-activated receptor gamma Rattus norvegicus 50-59 24454335-3 2013 Our study was focused on the effects of a PPAR gamma agonist pioglitazone (PIO) on blood pressure regulation, vasoactivity of vessels, and redox-sensitive signaling at the central (brainstem, BS) and peripheral (left ventricle, LV) levels in young prehypertensive rats. Pioglitazone 61-73 peroxisome proliferator-activated receptor gamma Rattus norvegicus 42-52 22995601-1 2012 Thiazolidinediones (TZDs), pioglitazone, rosiglitazone and troglitazone, the synthetic agonists for the PPARgamma, administered prior or during ischemic insult improve stroke outcome in rodents, post-occlusion treatments yielded inconsistent results. Pioglitazone 27-39 peroxisome proliferator-activated receptor gamma Rattus norvegicus 104-113